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Abstract 
The genome is comprised of a simple quaternary code that serves as the “software” 
which governs all the complex processes of life. The successful manipulation of this 
code holds enormous potential for applications involving genome engineering. 
However, the tools needed to navigate the complex landscape of the genome and 
efficiently and precisely introduce engineered modifications are lacking. The 
clustered regularly interspaced short palindromic repeats (CRISPR) adaptive immune 
system found in prokaryotes functions to recognise and silence foreign pathogenic 
DNA by double-stranded break (DSB) DNA digestion. The type II CRISPR system of 
Streptococcus pyogenes has recently been reconstituted to function in mammalian 
cells as a highly programmable and efficient gene-targeting nuclease platform. 
Through the heterologous expression of the CRISPR associated (Cas) 9 endonuclease 
and a small single-guide RNA (sgRNA) molecule, specific gene sequences can be 
targeted for a DNA DSB. The repair of this targeted DNA damage can be exploited to 
mutate gene sequences or reconstitute break sites according to a homologous repair 
template for precise gene modifications. In this study, the capabilities of the CRISPR/
Cas9 system for genome editing was tested by using it to precisely mutate the KRAS 
proto-oncogene. A panel of five KRAS targeting sgRNAs were designed around a 
common G>T mutation in codon 12 and characterised. The ability of the CRISPR/
Cas9 system to stimulate DSBs in this region was assessed using the Surveyor Assay, 
which is able to detect the non-homologous end joining repair of these breaks. A 
maximum cleavage activity of 6.01 and 2.74% was detected, upstream and 
downstream of the mutation site, respectively. Simultaneous cleavage by these two 
sgRNAs was able to successfully introduce a locus-specific micro-deletion. The 
homology directed repair of these DSBs according to a 90-mer single-stranded 
oligodeoxynucleotide repair template was shown with the RFLP assay. Analysis of 
these results implicated guide sequence composition and DSB repair pathway bias as 
potential factors which may affect the efficiency of desired gene-editing outcomes. 
These characterised sgRNAs were then applied to generate selectable G>T KRAS 
mutants. A “dual-cut” strategy, which was designed to overcome gene conversion 
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limitations was employed, and the outcomes were measured with qPCR. The results 
show that 0.123% of transfected cells were successful recombinants, demonstrating 
that the use of a “dual-cut” strategy with the CRISPR/Cas9 system was functional and 
efficient for the generation of knock-in mutants. The CRISPR/Cas9 system has 
proven to be efficient and robust in modifying the human KRAS locus in various 
ways. With its modularity and simplicity, CRISPR/Cas9 is a powerful tool that will 
allow for the modification and interrogation of gene function.  
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1. Introduction 
1.1 Genome Engineering 
The ability to understand and exploit the genetic code that governs all the complex functions 
of life, relies heavily on our ability to manipulate the molecules that constitute it. Genome 
engineering involves applying targeted genetic modifications into the genome of a living 
system for this purpose. The manipulation of DNA began in the 1970s when our basic 
understanding of this code was born. This led to the emergence of recombinant DNA 
technologies, allowing biologists to manipulate DNA and study the function of genes and 
gene systems, and also employ them for human benefit. These technologies have been 
particularly relevant with the increasing availability and capacity to rapidly read entire 
genomes. Genome engineering using recombinant DNA technologies have allowed us to 
functionally decipher large volumes of gene sequence data generated by high-throughput 
sequencing. Through the process of systematic reverse engineering, the function of many 
causal genetic elements have been elucidated and validated. In this way, interesting and 
useful biological molecules and pathways have been uncovered and studied. Furthermore, the 
understanding of these genomic elements and the ability to manipulate their code, has 
allowed for the routine reprogramming and engineering of life. 
Despite the exponential growth in the capacity to synthesise, manipulate and analyse DNA (a 
trend reminiscent to Moore’s Law), the successful engineering of DNA in the context and 
scale of the genome has been rather limited (Carr and Church, 2009). Tools that are capable 
of navigating the complex landscape of the genome, at the resolution of the single nucleotide 
level, and facilitating the efficient introduction of precise genomic perturbations have been 
the rate-limiting step. Without these tools, hypotheses based on observational data derived 
from the genome cannot be rapidly or easily validated, preventing these biological models 
from being applied to advance basic research, biotechnology and medicine. 
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1.2 Gene Targeting 
The technology to make precise targeted alterations to the mammalian genome first came 
about in the 1980s, when Mario Capecchi and Oliver Smithies showed that newly introduced 
DNA constructs could be stably inserted into specific genomic loci by homologous 
recombination (HR). Before this, the introduction of novel DNA into the genome was 
mediated by retroviral vectors, which sometimes integrated their DNA payload into random 
sites, causing unwanted insertional mutagenesis (Wirt and Porteus, 2012). Gene targeting, 
however, involved the integration of a gene targeting DNA construct into the target sites of 
interest within the genome, that were highly homologous. Successful recombination events 
resulted in the linear transfer of genetic material from the exogenous donor DNA to the 
endogenous target site, in a process known as gene conversion (Smithies et al., 1985). This 
breakthrough technique has been the cornerstone of genome engineering, enabling molecular 
biologists to generate knock-out and knock-in cell and animal models for decades (Mussolino 
and Cathomen, 2012).  
Despite this, the efficiency of gene targeting is extremely poor, as spontaneous and targeted 
HR with exogenous gene targeting DNA occurs at a rate of 10-6-10-8 in cultured mammalian 
cells (Wirt and Porteus, 2012). Because of the rarity of this event, the use of gene targeting to 
produce and isolate isogenic cell lines that recapitulate genetic perturbations of interest is 
very challenging. Current strategies involve the enrichment of cell populations that have 
successfully undergone the targeted gene modification, by concurrently knocking-in a gene 
that would imbue the cell with an advantageous phenotype under selective conditions. From 
this, clonal cell colonies can be isolated and expanded into recombinant cell lines. This was 
first demonstrated in cultured human cells by work done by Oliver Smithies, who showed 
that the neo gene could be stably integrated into the β-globin locus by HR, and expressed to 
allow for the selection of recombinants using the aminoglycoside antibiotic G418 (Smithies 
et al., 1985). However, the high frequency of non-homologous recombination in mammalian 
cells often results in the selection of clones that have recombined at illegitimate genomic 
sites. This produces a large number of false positive clones that add to the screening process. 
In order to overcome this, a positive-negative selection system was developed to decrease the 
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yield of illegitimate recombinants (Capecchi, 1989). This system is made up of two 
independent expression cassettes. The neo expression cassette is designed to be flanked by 
two homology arms that will direct its integration into the target site by HR. The Herpes 
Simplex Virus thymidine kinase (HSV-tk) gene is placed adjacent to the region of homology, 
and its integration is excluded when on-target HR occurs. Only off-target integration of the 
gene targeting DNA, by non-homologous recombination, will retain the HSV-tk cassette. In 
the first round of positive selection, G418 is used to select for cells that have experienced 
recombination and harbour the neo cassette. The HSV-tk expression cassette is then used to 
negatively select for cells that have specifically undergone targeted HR. In the presence of 
gancylcovir, illegitimate recombinants that express the HSV-tk, as a result of random 
integration, are killed off. The use of this dual selection strategy has improved the rate at 
which positive clones are selected. However, this process requires the production of large 
gene targeting vectors to accommodate the two selection cassettes and the two homology 
arms, which are often between 2-4 kb in length each, to achieve sufficient HR (Capecchi, 
1989). Furthermore, the requirement for two subsequent selection steps makes this a very 
time consuming process.  
An alternative to preventing the enrichment of random recombinants is the use of a promoter 
trap strategy (Sedivy and Dutriaux, 1999). This relies on the integration of the selection 
cassette, in frame, into an exon of the targeted gene so that its expression can be driven by the 
endogenous upstream promoter. Translation of the selection cassette can then subsequently 
occur from the native start codon to produce a fusion protein. This strategy has been shown to 
decrease the selection of random recombinants as the chances of the targeting vector 
integrating in frame into the exon of a random active off-target gene is quite low (Sedivy and 
Dutriaux, 1999). However, this strategy is only limited to genes that are being actively 
expressed in the cells used. Also, the integration of the selection cassette will result in the loss 
of function of the targeted gene, and provisions must be made to replace the disrupted exon 
or remove the selection cassette, after the selection process, to maintain gene functionality. 
Both these strategies involve the production of large and cumbersome gene targeting vectors, 
which simply serve to enhance the recovery and enrichment of the rare cells that harbour the 
desired genetic modifications. Methods that enhance the rate of HR at the target site, to 
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increase the obtainable yield of successful recombinants, may be more favourable for gene 
editing applications. 
The delivery of gene targeting DNA constructs into cells using recombinant adeno-associated 
virus (rAAV) vectors has been shown to increase the rate of targeted HR by a factor of 25-
fold compared to naked plasmid-based approaches (Topaloglu et al., 2005). This is because 
the AAV genome has been found to be intrinsically highly recombinogenic, aiding the HR of 
gene targeting DNA with the genomic target sequence. AAVs are composed of a 4.7 kb 
single-stranded DNA genome which is flanked by two short stretches of double-stranded 
DNA (dsDNA) known as the inverted terminal repeats (ITRs) (Vasileva et al., 2006). It is 
thought that the single-stranded nature, and its transition from being single-stranded to 
double-stranded at the ITRs, of AAV genomes, recruit DNA repair proteins or complexes 
which facilitate and enhance viral DNA integration via HR (Russell and Hirata, 1998, 
Vasileva et al., 2006). Furthermore, rAAVs are able to infect a large number of different cell 
types and efficiently deliver intact gene targeting DNA into the cell, which further improves 
the efficiency at which HR can occur. rAAVs have been shown to be able to target genes at an 
efficiency of 1% under optimal conditions (Khan et al., 2011). But even with this high 
efficiency of gene targeting, successfully modified cells still need to be selected for from the 
entire cell population (Porteus, 2007). This necessitates the inclusion of a selection cassette 
along with the two homology arms and the intended genetic modification in the viral gene 
targeting DNA construct. However, this can be challenging as the size of the construct is 
limited by the small packaging capacity of AAVs. The tradeoff often made to include all these 
elements within a virion particle is the use of shorter homology arms, which sacrifices HR 
efficiency. Furthermore, it has been shown that rAAVs are relatively inefficient at targeting 
silent loci, which limits its versatility for gene editing applications. The production of highly 
concentrated and pure rAAV stocks, a requisite for efficient transduction, is also technical and 
time consuming (Khan et al., 2011). Even though rAAVs are able to significantly stimulate 
HR, several factors limit the ease and versatility at which rAAVs can be used for gene 
targeting. 
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Targeted DNA double-stranded breaks (DSBs) have been shown to increase the frequency of 
HR at the DSB site by a factor of 1 000-fold or more in mammalian cells (Chen et al., 2007). 
This is because chromosomal breaks stimulate the high fidelity homology-directed repair 
(HDR) response, which relies on a homologous template to seamlessly reconstitute the 
damaged site (Yang et al., 2013). Therefore, the efficiency of gene targeting can be 
dramatically enhanced by introducing a targeted DSB along with a homologous repair 
template to stimulate HDR and subsequent gene conversion (Chen et al., 2007). In this way, 
homologous repair templates can contain 200-800 bp long homology sequences, as the 
stimulation of HDR by the targeted DSB, is able to sufficiently compensate for the use of 
shorter homology arms. This makes the construction of donor repair templates significantly 
simpler than traditional gene targeting vectors (Chen et al., 2011). Furthermore, these repair 
templates are not limited by any design constraints, such as the size limits associated with the 
use of rAAVs, allowing for multiple selection cassettes and gene modifications to be 
included, and various selection strategies to be employed. The repair of DNA DSBs by the 
alternative error prone non-homologous end joining (NHEJ) pathway further expands the 
achievable repertoire of targeted gene modifications in mammalian cells (Kim and Kim, 
2014). NHEJ occurs by the re-ligation of the broken DNA ends at the DSB site, in the 
absence of a repair template. In this process, small insertions and deletions (indels) are 
introduced into the repair site, which results in the targeted mutagenesis of the gene (Kim and 
Kim, 2014) (Figure 1). The resolution of DNA DSBs by these common mammalian repair 
pathways each yield distinct genetic modifications that are useful for genome engineering. By 
introducing a DSB at a specific target site, a variety of genetic modifications can be made, 
ranging from gene mutagenesis and gene deletions, to the efficient introduction of very 
precise gene alterations using donor repair templates. 
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Figure 1: A schematic illustrating the two common DNA repair pathways of DSBs in mammalian cells. In 
the absence of a homologous repair template, NHEJ is stimulated. This involves the re-ligation of the broken 
DNA ends together and in the process small, mutagenic, insertions and deletions are included in the repaired 
gene sequence. HDR involves the re-sectioning of the broken DNA ends, which invade a homologous repair 
template. The damaged DNA is re-synthesised according to the repair template, allowing for the introduction of 
precise gene modifications. 
1.3 Designer nucleases 
Targeted chromosomal DSBs, for the stimulation of HDR in mammalian cells, can be 
achieved through the use of endonucleases to cleave specific genomic sites. This was first 
demonstrated with the yeast-derived homing endonuclease I-SceI (Wirt and Porteus, 2012). 
This homing endonuclease recognises and cleaves an 18 bp non-palindromic sequence, which 
is predicted to occur only every 7×1010 bp, assuming that the base pairs of the genome being 
targeted are randomly distributed (Wirt and Porteus, 2012). This small target space severely 
limits the use of this homing endonuclease for gene targeting purposes. Because of this, the 
use of I-SceI has mostly served as a proof-of-concept to demonstrate that targeted DSBs can 
stimulate HDR for gene editing. In these studies, the I-SceI recognition sequence was 
integrated into dysfunctional neo or eGFP expression cassettes, which were then targeted for 
HDR correction. These repaired constructs were then detected through the selection of cells 
that displayed the relevant phenotype (Wirt and Porteus, 2012). In order to introduce 
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chromosomal breaks at specific target sites of interest within the genome, endonucleases that 
have programmable sequence recognition characteristics are needed. Designer nucleases, 
such as chemical nucleases, meganucleases, zinc-finger nucleases (ZFNs) and transcription 
activator-like nucleases (TALENs), can be programmed to recognise and target specific 
genomic sequences. By employing these nucleases in genome engineering strategies, the 
endogenous DNA repair pathways found in mammalian cells can be exploited for the 
versatile and efficient modification of genomic gene sequences. 
ZFNs are one of the platforms that have successfully gone into the mainstream for genome 
engineering purposes. ZFNs are chimeric proteins that have been shown to be able to 
introduce targeted DSBs within the genome, and stimulate HDR (Porteus and Carroll, 2005). 
These nucleases are based on the ubiquitous mammalian Cys2-His2 zinc-finger DNA 
recognition domain, which is fused to the catalytic domain of the FokI endonuclease for DNA 
DSB induction. ZFNs are designed to function as obligate pairs, which dimerise at the target 
site to form an active FokI homodimer (Porteus and Carroll, 2005). The target specificity of 
each ZFN pair is dictated by a tandem array of 3-6 monomers, which each bind to 3-4 
nucleotides (Chhabra, 2014). This particular DNA recognition resolution has limited the 
target space of ZFNs to only 1 site in every 100 bp on average, in the human genome. 
Furthermore, the construction of ZFNs is a labour intensive process, that is not feasibly 
scalable to large genomic studies (Carroll, 2011). Despite extensive engineering to improve 
these nucleases, their adoption for genome engineering applications has been relatively poor. 
TALENs have proven to be far more robust than ZFNs, and currently serve as the gold 
standard in the gene editing toolbox. TALENs have been adapted from plant bacterial 
pathogens which use these DNA binding molecules to modulate host gene expression during 
infection (Mussolino and Cathomen, 2012). The DNA binding domain of TALENs consist of 
tandem arrays of 33-35 amino acid repeats. Each repeat module is able to recognise a single 
nucleotide through a corresponding variation of two amino acids at the twelfth and thirteenth 
position of each repeat. These are known as the repeat variable diresidues (RVDs) (Kim and 
Kim, 2014). Following a simple amino acid to DNA cipher, TALENs have been constructed 
with 18-20 repeat modules and can be potentially configured to target any user-defined 
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genomic space (Boch et al., 2009). Similar to ZFNs, the DNA recognition module of 
TALENs is fused to the FokI cleavage domain and function as obligate pairs for activation. 
This robust architecture has been widely adopted for various applications and even scaled up 
for high-throughput applications. However, the construction of these molecules still remains 
very time consuming and technical (Li et al., 2014). 
The use of these designer nucleases to stimulate DNA repair pathways at specific genomic 
targets sites has been the driving force of genome engineering. This strategy is currently the 
most efficient way to precisely edit the human genome (Yang et al., 2013). However, despite 
the modular design and programmability of both ZFNs and TALENs, the need to completely 
re-engineer the protein-based recognition module to target different genes is inefficient. Also, 
recognition module position bias inherent to these two platforms, has been demonstrated to 
adversely affect their robustness. It has been shown that the activity of certain module 
combinations are unpredictable and inefficient (Carroll, 2011, Carroll and Beumer, 2014). 
Furthermore, the technical complexities and intense labour requirements to generate a single 
pair of these nucleases render these platforms undesirable and unfeasible for the systematic 
interrogation of entire genomes, or the rapid construction of model systems that recapitulate 
genetic elements of interest. Currently, there is the need for the development of new genome 
engineering tools that can robustly and efficiently mediate various gene perturbations in a 
highly specific manner. Moreover, in the current genomics era, these tools need to be highly 
programmable and easily scalable, through a construction and implementation process that is 
simple, rapid and cost-effective (Perez-Pinera et al., 2012). The development of such 
powerful, yet simple tools, will allow the exploration of the genetic code to expand to the 
scale of the genome. 
1.3.1 RNA-guided endonucleases 
The clustered regularly interspaced short palindromic repeats (CRISPR) and the CRISPR-
associated (Cas) proteins constitute an adaptive immune system found in bacteria and 
archaea, which functions to silence foreign DNA by RNA-guided nucleolytic digestion 
(Barrangou et al., 2007, Brouns et al., 2008, Marraffini and Sontheimer, 2008). There are 
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three types (I-III) of the CRISPR/Cas system that have been identified in various prokaryotic 
species, which each have the same general mode of function to achieve acquired immunity 
(Barrangou and Marraffini, 2014). In each type, the organism is immunised through the 
integration of short fragments of the invading nucleic acids into the CRISPR locus. 
Expression and maturation of these sequences (also known as spacers) yields individual 
CRISPR RNAs (crRNAs), which each contain the exogenously-derived spacers for target 
recognition by Watson and Crick base-pairing. DNA interference occurs through the crRNAs 
binding with the effector Cas protein component and guiding it to the cognate DNA sequence 
(also known as the protospacer) for digestion (Barrangou and Marraffini, 2014). Successful 
binding of the Cas ribonucleoprotein complex to the target DNA sequence requires the 
recognition of the protospacer adjacent motif (PAM). This is a short recognition sequence 
directly adjacent to the target sequence, which serves in the identification of potential spacer 
sequences in the immunisation process, as well as foreign target DNA recognition to avoid 
auto-immunity (Mojica et al., 2009, Paez-Espino et al., 2013). The sequences of these motifs 
have been identified in various species that make use of the type I and type II systems, 
however, they still need to be characterised for the type III system (Barrangou and Marraffini, 
2014). 
The CRISPR/Cas system types are defined by the various Cas proteins involved in achieving 
this kind of immune response. The type I and type III system rely on the assembly of a large 
multisubunit complex of Cas proteins for crRNA maturation and target cleavage activity 
(Brouns et al., 2008, Hatoum-Aslan et al., 2013). The type II system is able to execute these 
functions through the use of a single Cas polypeptide, Cas9, making it the most minimalistic 
CRISPR/Cas system identified and the most extensively studied (Gasiunas et al., 2012). The 
type II CRISPR locus encodes the Cas9 endonuclease and two non-coding RNAs: the 
precursor-CRISPR-RNA (pre-crRNA) array, which consists of unique exogenously-derived 
guide spacer sequences that are interspaced by short direct repeats, and the trans-activating 
CRISPR RNA (tracrRNA) (Fonfara et al., 2014). The process in which these components 
function to achieve adaptive immunity with the type II system was first demonstrated in 
Streptococcus pyogenes (S. pyogenes) SF 370 and involves the following 3 phases (Figure 2) 
(Deltcheva et al., 2011): 
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1. Adaptation phase - Under a viral or plasmid challenge, S. pyogenes is able to respond by 
integrating fragments of the foreign DNA into the CRISPR array to acquire new spacer/
guide sequences that serve to recognise the target. Accompanying theintegration of these 
new spacers into the 5ʹ end of the array, the repeat sequence is duplicated so that the 
architecture of the CRISPR array is maintained (Jinek et al., 2012). 
2. Expression phase - The entire CRISPR array is expressed to generate a pre-crRNA 
transcript that is made up of multiple spacer-repeat units in tandem. Expressed tracrRNA 
molecules bind to the repeat regions of the pre-crRNA array by 25 conserved and 
complementary nucleotides. This initiates the maturation process, which involves the 
tracrRNA-pre-crRNA array complex being cleaved by RNase III, in the presence of 
Cas9, to yield mature individual tracrRNA:crRNA units. Mature crRNAs are 39-42 
nucleotides long. On the 5ʹ end of these, is a unique 20 nucleotide guide sequence 
derived from the spacer regions of the array, for target recognition. The 3ʹend consists of 
a 14 nucleotide long CRISPR repeat sequence that is bound to the mature tracrRNA, 
forming the repeat:anti-repeat duplex. The tracrRNA is 89 nucleotides long, with the 
remaining unbound nucleotides forming a tracrRNA tail that folds itself into a secondary 
structure that consists of a tetra-loop followed by 3 stem loops. These structural features 
have been found to be important for interactions with Cas9 (Jinek et al., 2012, Nishimasu 
et al., 2014).   
3. Interference phase - The mature crRNA is then loaded into the Cas9 endonuclease, which 
is comprised of two catalytic domains. The HNH domain and the RuvC-like domain 
cleave the complementary and the non-complementary strand of double-stranded DNA 
(dsDNA), respectively (Jinek et al., 2012). The loading of the crRNA activates the Cas9 
endonuclease, through conformational rearrangements of its catalytic cores (Jinek et al., 
2014). This forms an RNA-protein complex that is able to recognise target DNA 
sequences that are complementary to the 20 nucleotide guide sequence of the loaded 
crRNA. The successful binding of the crRNA-Cas9 complex to the target, or protospacer 
sequence, is mediated by the recognition of an obligatory PAM. This is located directly 3ʹ
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of the target sequence. With this, the crRNA-Cas9 complex destabilises the target DNA 
duplex and initiates strand invasion, whereby the appropriate strands of the target are 
loaded into the Cas9 catalytic cores for cleavage. A DSB is generated exactly 3 bps 
upstream of the PAM site, to produce blunt-ended products (Sternberg et al., 2014). For 
the type II system in S. pyogenes, the PAM recognition motif is NGG, but cleavage 
activity with a NAG motif has also been observed, albeit at a much lower efficiency (Hsu 
et al., 2013). 
Figure 2: A schematic showing the function of the CRISPR/Cas9 system in S. pyogenes. The type II 
CRISPR/Cas9 system found in S. pyogenes is comprised of two non-coding RNA components (the crRNA and 
the tracrRNA) and the catalytic Cas9 endonuclease. crRNA is produced from the CRISPR array, which is 
expressed as a single transcript that gets processed into individual, active crRNA:tracrRNA complexes. These 
tracrRNA:crRNA complexes are able to activate the Cas9 endonuclease and direct it to cleave DNA sequences 
that are complementary to the guide or spacer sequence (green) and are directly upstream of a PAM recognition 
motif (red). 
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Recently, various type II CRISPR/Cas9 systems (from S. pyogenes, Streptococcus 
thermophilus and Neisseria meningitidis) have been successfully reconstituted to function in 
mammalian cells through the heterologous expression of Cas9 and the tracrRNA and pre-
crRNA components (Fonfara et al., 2014). In a system developed by Zhang et al., a human 
codon-optimised version of S. pyogenes Cas9 and the pre-crRNA and tracrRNA components 
were expressed from independent promoters from a single plasmid. The Cas9 component was 
flanked by two nuclear localisation signals and was expressed from the elongation factor 1α 
promoter. The two RNA components were expressed from their own U6 Pol-III promoters 
(Figure 3A) (Cong et al., 2013). This system has been shown to successfully mimic the native 
CRISPR/Cas9 system of S. pyogenes in mammalian cells, whereby endogenous RNase III is 
able to mediate the maturation of the pre-crRNA and tracrRNA to form an active complex 
with the Cas9 endonuclease and guide it to the specified target for DSB induction (Cong et 
al., 2013).  
In an attempt to develop a more efficient and facile system, two independent groups used a 
tetra-loop to fuse the 5ʹ end of the tracrRNA and 3ʹ end of the crRNA component into a single 
chimeric molecule, which was expressed from one promoter. This single-guide RNA 
(sgRNA) v1.0 was composed of a full length, mature crRNA (42 nucleotides) and a truncated 
tracrRNA (RNA scaffold), which retained the minimum number of nucleotides (position 
23-48) to maintain functionality (Figure 3B) (Jinek et al., 2012, Cong et al., 2013). The use of 
sgRNA v1.0 was expected to improve the cleavage efficiency of the CRISPR/Cas9 system, as 
its function bypasses any bottlenecks associated with the expression and complexing of the 
crRNA and tracrRNA as individual components, and the process of tracrRNA:crRNA 
maturation. However, it was shown that this chimeric sgRNA v1.0 design consistently 
performed poorly compared to the tracrRNA:crRNA duplex configuration when targeting the 
EMX1 gene in mammalian cells (Cong et al., 2013). Subsequent optimisation of this sgRNA 
architecture produced the sgRNA v1.1 design, which is a chimeric molecule that more closely 
resembles the wild-type (WT) tracrRNA:crRNA duplex. This was achieved by lengthening 
the RNA scaffold tail to the native 89 nucleotides, which significantly improved the cleavage 
efficiency of the system to levels that were comparable or exceeded that seen with the 
tracrRNA:crRNA duplex configuration (Hsu et al., 2013). This can be attributed to the RNA 
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scaffold tail assuming the secondary structural loops which have been shown to be important 
for sgRNA loading and activation of the Cas9 protein (Nishimasu et al., 2014). In other work 
done by Huang et al., the CRISPR/Cas9 system was repurposed to label and visualise specific 
genomic loci in living cells. By tagging eGFP to a deactivated form of Cas9 (dCas9), the 
improved sgRNA design was still not able to efficiently form distinct observable puncta, 
which represent target-bound sgRNA:dCas9 complexes. From this it was found that the 
sgRNA architecture was still not being efficiently expressed or loaded into the dCas9 to form 
an active complex. A putative Pol-III terminator sequence (4 consecutive U’s) in the crRNA 
sequence of the sgRNA was identified. In order to prevent this from prematurely stopping the 
expression of sgRNA v1.1, the terminator sequence was abolished by an A-U base swap in 
the repeat:anti-repeat duplex region. To further improve the loading of sgRNA v1.1, the 
repeat:anti-repeat duplex region was also extended so that it more closely mimicked the 
length used in the tracrRNA:crRNA duplex design (Figure 3C). These improvements have 
been shown to significantly improve the production of active sgRNA:dCas9 complexes 
(Chen et al., 2013). It is predicted that the benefits of these changes to the sgRNA 
architecture will carry through to its use with the active Cas9 endonuclease for gene 
targeting.  
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Figure 3: The evolution of the tracrRNA:crRNA complex design for the efficient and simple use of 
CRISPR/Cas9 in mammalian cells. (A) The original tracrRNA:crRNA design was a copy of the WT 
architecture found in S. pyogenes. This involved the expression of the crRNA and tracrRNA as separate 
components from two different promoters. The function of this design relied on the formation of the 
tracrRNA:crRNA complex through base-pair interactions between the direct repeat:anti-repeat region of each 
RNA component and its subsequent maturation. (B) The sgRNA fused the crRNA and tracrRNA components 
together via a tetra-loop, to produce a very minimalist chimeric molecule, which could be expressed from a 
single promoter and mimicked the natural crRNA:tracrRNA architecture. (C) Improvements to the sgRNA 
design involved removing a premature Pol-III terminator sequence and extending the repeat:anti-repeat stem, as 
well as the RNA scaffold. 
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The evolution of the CRISPR/Cas9 system for its use in mammalian cells has produced a 
very minimalistic and efficient system for genome engineering. By simply expressing Cas9 
and a sgRNA containing the guide sequence of interest, almost any genomic sequence can be 
targeted for modification. This presents a completely new tool that is easy to engineer and 
implement for the introduction of targeted DSBs in the mammalian genome. Comparing this 
system to existing platforms, CRISPR/Cas9 has been estimated to have 1 target site in every 
8 bp on average in the human genome, if the NGG PAM constraint of S. pyogenes is adhered 
to (Cong et al., 2013). This statistic is increased to every 1 in 4 bp if the degenerate NAG 
PAM is also considered (Hsu et al., 2013). The use of Cas9 derived from different bacterial 
species, which have different PAM requirements, may further improve the size of this target 
space. A recent study provides a collection of divergent PAM sequences recognised by 
several species of bacteria, which could be used to improve the genome editing capabilities of 
the CRISPR/Cas9 system (Fonfara et al., 2014). For example, the Cas9 of Neisseria 
meningitidis requires a PAM sequence of NNNNGATT, which is significantly different to the 
PAM of S. pyogenes, expanding the targetable sequence space in the mammalian genome 
(Hou et al., 2013). Alternatively, the PAM sequence for Francisella novicida is NG, which is 
extremely short and non-specific, placing minimal constraints on target sequence selection 
(Fonfara et al., 2014). Therefore, through the development and use of Cas9 orthologs, which 
have evolved to use different PAM sequences, it is likely that the entire mammalian genome 
can be targeted with the CRISPR/Cas9 system. Furthermore, as the understanding of the 
interaction between the sgRNA:Cas9 complex and the target DNA PAM site improves, the 
Cas9 protein could potentially be engineered to have different PAM specificities by rational 
design (Anders et al., 2014). The activity of this system has also been shown to be 
comparable, and in some cases, exceed that of TALENs, making it a suitable candidate to 
replace this gold standard (Hendel et al., 2014).  
Besides having robust activity, the simplicity of reprogramming the Cas9 target specificity, 
through the expression of different sgRNAs, is highly advantageous for genome engineering 
applications. This has been demonstrated in several recent studies. For example, the high-
throughput capability of this system was demonstrated in a genome-wide knock-out screen. 
In this work, a library of sgRNAs designed to target over 18 000 genes was used for a 
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negative selection screen to identify important genes for cell viability and proliferation. It was 
found that sgRNA species that targeted genes essential for ribosomal function were depleted, 
as these cells failed to survive or proliferate robustly within the cultured cell population. This 
library was further used in a positive selection screen, in which genes that play a role in the 
resistance to vemurafenib, a therapeutic for treating melanoma, were identified. In this 
screen, sgRNA species that were enriched were used to identify genes important for drug 
resistance, as their loss of function provided the cells with a survival advantage under 
treatment conditions (Shalem et al., 2014). From this, it was demonstrated that the CRISPR/
Cas9 system is able to be feasibly employed for genome-wide knock-out screens. Moreover, 
by interfering with the gene sequence directly, complete knock-out was achieved, which 
cannot be done using the conventional RNA interference approach. The CRISPR/Cas9 
system has also been used to generate animal models with multiple gene mutations in a single 
step. This was done by co-injecting the Cas9 mRNA and different sgRNAs into mouse 
zygotes to generate mice with biallelic mutations in multiple genes (Wang et al., 2013). This 
method circumvents the tedious process of cross-breeding mice with single mutations to 
achieve the same result. CRISPR/Cas9 is also not limited to only generating targeted DSBs. 
By inactivating the catalytic domains of the Cas9 endonuclease to produce a dCas9, (which 
still maintains its reliance on sgRNAs for specific sequence targeting), the CRISPR/Cas9 
system has been used to modulate and explore the genome in other ways. These include 
fusing transcription factors or repressors to dCas9 and guiding this complex to particular 
genomic loci to modulate gene expression (Qi et al., 2013). Other applications involve using 
the CRISPR/Cas9 platform for visualising the spatio-temporal architecture of the genome in 
living cells by tagging dCas9 to fluorescent molecules (Chen et al., 2013). This demonstrates 
the versatility of the CRISPR/Cas9 system, which can be adapted to be used as a generic gene 
sequence targeting platform, which presents users with a new tool to easily, efficiently and 
creatively explore the genome. 
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1.4 Targeting KRAS with CRISPR/Cas9 
CRISPR/Cas9 system is a simple, but extremely powerful and versatile tool for modifying 
and interrogating the genome. To test this technology and explore different strategies to 
optimise its function for genome engineering, the targeted mutation of the KRAS proto-
oncogene was used as a model system to investigate this. Kras is part of the extracellular 
signal-regulated kinase (ERK) signalling pathway (Gollob et al., 2006). This pathway 
functions to transmit extracellular stimuli, through a signal transduction cascade, into the 
nucleus of the cell. Kras serves as an intermediary component in the cytoplasm, in which its 
activation by the epidermal growth factor receptor (EGFR) catalyses the conversion of a 
bound GDP to GTP. This activated Kras then subsequently activates the downstream kinase 
activity of Braf, to relay the input signal. The activity of Kras is self-regulated by an intrinsic 
competing GTPase, which abrogates its transduction activity by removing the GTP molecule. 
Several activating point mutations have been found to commonly occur at codons 12, 13 and 
61 of KRAS, which eliminates the regulatory GTPase activity (Gollob et al., 2006, Loupakis 
et al., 2009). This results in the production of a constitutively active form of Kras, which 
continuously stimulates the ERK pathway. This has been commonly observed in various 
cancer types, providing the transformed cells with enhanced growth and proliferative 
characteristics (Heinemann et al., 2009).  
1.5 Aims and objectives 
The aim of this study was to assess the functionality of the CRISPR/Cas9 system for genome 
editing. The system was tested by programming it to target the KRAS gene in human cells. 
The ability of CRISPR/Cas9 to precisely target and modify this gene locus was assessed 
based on the efficiency of cleavage and the subsequent repair outcomes of the DSBs. 
Subsequent to this, a “dual cut” strategy using the CRISPR/Cas9 system was implemented to 
recapitulate an oncogenic KRAS mutant variant in a cell-based model system. In order to 
achieve this, the following general objectives were set out: 
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1. Testing the CRISPR/Cas9 system for the modification of the KRAS gene 
Five sgRNAs (using the sgRNA v1.1 architecture) were designed to mediate DNA DSBs 
around a common oncogenic G>T mutation hotspot in codon 12, exon 2 of the human KRAS 
gene (Loupakis et al., 2009). The cleavage activity of each sgRNA was assessed by 
measuring the NHEJ-mediated repair of DSBs. The ability of the CRISPR/Cas9 system to 
stimulate HDR, for the precise modification of the KRAS gene, was also tested by repairing 
individual DSBs, as well as a micro-deletion, using short single-stranded 
oligodeoxynucleotides (ssODNs) as repair templates. 
2. Using the CRISPR/Cas9 system to generate selectable G>T KRAS mutants 
The CRISPR/Cas9 system was used to modify the KRAS gene to recapitulate the oncogenic 
G>T mutation in recombinant cells. A “dual cut” strategy, which was designed to facilitate 
the co-integration of a selection cassette and the point mutation, was simulated. The 
outcomes of this gene editing strategy was assessed to determine the efficiency of producing 
selectable KRAS mutant recombinants, which can be developed into an isogenic cell line 
model for further study. 
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2. Materials and Methods 
2.1 Tissue Culture 
Human embryonic kidney (HEK) 293 cells were cultured in a laminar flow cabinet under 
sterile conditions. A 2 ml tube of frozen cells (stored in freeze medium (Appendix 7.3.1)) was 
quickly thawed and added to 10 ml of complete DMEM, which was composed of Dulbecco’s 
Modified Eagle Medium (DMEM): F 12 mixture, containing glucose, HEPES buffer and L-
glutamine (Lonza, USA), and was further supplemented with 10% heat-inactivated foetal 
bovine serum (FBS) (Hyclone, USA) and 0.2% penicillin-streptomycin (pen/strep) antibiotic 
mix (Lonza, USA). The cells were pelleted by centrifuging the cell suspension at 200×g for 
3 minutes (Minor MSE), after which the supernatant was completely discarded and the pellet 
resuspended in 10 ml of complete DMEM and added to a T-75 (75 cm3) flask. HEK 293 cells 
were incubated in a 37°C humidified incubator (Thermo Forma, USA), with 5% CO2.  
Cell proliferation was periodically monitored with an inverted light microscope (Zeiss 
Axiovert 25, Germany). Cultures that reached 70-80% confluency were sub-cultured. This 
involved discarding the cell culture medium and washing the cells with 5 ml of 1X phosphate 
buffered saline (PBS) (Appendix 7.3.10). The adherent cells were detached by adding 2.5 ml 
of Trypsin-EDTA (Hyclone, USA) and incubating them for 2-3 minutes at 37°C. After this, 
2.5 ml of complete DMEM was added to neutralise the trypsin. The cells were then pelleted 
by centrifuging the mixture at 200×g for 3 minutes (Minor MSE, UK). The supernatant was 
discarded and the pellet resuspended in 10 ml of complete DMEM and split between two 
flasks. A further 5 ml of complete DMEM was added to each flask to obtain a final volume of 
10 ml for each culture. 
For experiments, cell counts were determined by mixing a small volume of the harvested 
cells with Trypan Blue (Hyclone, USA) at a 1:1 ratio, and loading 10 µl of this into a 
counting chamber of a disposable haemocytometer slide (Immune Systems, UK). Because 
Trypan Blue permeates the cell membranes of dead cells, they stain blue. The “white”, living 
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cells, within 5 large squares were counted and the concentration of cells calculated according 
to the following formula: 
 
The required number of cells for a particular experiment would be obtained by taking the 
appropriate volume of this cell suspension for further use. 
Cultured HEK 293 cells were periodically frozen to maintain a stock of low passage cells. 
This was done by detaching and harvesting the cells, as described above. For a T-75 flask, the 
cells were resuspended the in 16 ml of freeze medium (Appendix 7.3.1), and made into 2 ml 
aliquots which were stored in a -80°C freezer. 
2.2 Cloning 
2.2.1 sgRNA expression plasmids 
Five different sgRNA guide sequences targeting the exon 2 region of the human KRAS locus 
found on chromosome 12p12.1 (ENSG00000133703) were designed using the CRISPR 
design tool provided by the Feng Zhang group (http://crispr.mit.edu/). The tool identified all 
the potential sgRNA target sites within a 250 bp region of the G>T mutation site (125 bp in 
each direction) and generated a score that ranked the potential guide sequences according to 
various target specificity parameters (Hsu et al., 2013). Of the five sgRNAs chosen, three of 
these were designed to direct the Cas9 endonuclease to a region that is upstream of the G>T 
transversion in exon 2, to induce 5ʹ cleavages (sgRNA 224-226), and the remaining two to 
induce 3ʹ cleavages (sgRNA 227-228) that are downstream to the G>T modification. Each 
guide sequence was cloned into the pcDNA.H1.sgRNA vector (Appendix 7.5.1) for sgRNA 
expression. 
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2.2.1.1 Preparation of the expression plasmid 
The pcDNA.H1.sgRNA expression plasmid was shipped to the laboratory from the Scripps 
Research Institute on pieces of dried filter paper. To reconstitute the plasmid in solution, the 
filter paper was soaked in 20 µl of elution buffer from the QIAprep Spin Miniprep kit 
(Qiagen, Germany) containing 1.25 M NaCl, 50 mM Tris-Cl (pH 8.5) and 15% isopropanol 
(v/v), for 1 hour in a 1.5 ml microcentrifuge tube.  
For the bulk preparation of this plasmid, 2 µl of this DNA suspension was used to transform 
100 µl of competent E. coli Stbl3 cells (Appendix 7.4.1) that were thawed on ice. This 
mixture was allowed to rest on ice for 30 minutes before it was heat shocked at 42°C for 
90 seconds, exactly. The cells were allowed to recover on ice for 5 minutes. An additional 
outgrowth step was added to aid the survival of transformed bacteria under ampicillin 
selection conditions. 1 ml of LB broth (Appendix 7.3.3) was added to the transformation 
mixture and incubated for an hour at 37°C. The cells were then collected by centrifugation at 
720×g for 3 minutes (Eppendorf Centrifuge 5402, Germany). 800 µl of the supernatant was 
discarded, and the remaining volume was used to resuspend the pellet of bacterial cells. The 
cells were plated onto an ampicillin-LB agar plate (100 µg/ml final ampicillin concentration) 
(Appendix 7.3.5) and incubated for 14-16 hours in a 37°C incubator. Successfully 
transformed cells formed colonies that appeared on the antibiotic supplemented plate. A 
single colony was picked and inoculated into 100 ml of ampicillin-LB broth (100 µg/ml final 
ampicillin concentration) (Appendix 7.3.6). This bacterial culture was placed in a shaking 
incubator, set at 180 rpm, for 14-16 hours at 37°C, before the plasmid was extracted using the 
QIAprep Plasmid Midi kit (Qiagen, Germany), as directed by the manufacturer’s protocol 
(Appendix 7.4.3). The extracted plasmid was quantified using a Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies, USA) and diluted to 1 µg/µl stocks.  
2.2.1.2 Guide sequence ligation 
1 µg of the pcDNA.H1.sgRNA plasmid was digested with 10 U of BsmBI (10 U/µl stock 
concentration) (Thermo Scientific, USA) in a 20 µl reaction containing 10X Tango Buffer 
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(which contains 33 mM Tris-acetate (pH7.9 at 37°C), 10 mM Mg-acetate, 66 mM K-acetate 
and 0.1 mg/ml BSA) and deionised water (ddH2O). This reaction was incubated at 37°C for 1 
hour. After this, the entire reaction was mixed with 4 µl of 6X DNA Loading Dye (Thermo 
Scientific, USA) and loaded into a 50 ml 1% (w/v) agarose gel stained with 2 µl of ethidium 
bromide (10mg/ml stock concentration). 5 µl of Kapa Universal Ladder (Kapa Biosystems, 
USA) was used as a size marker. Electrophoresis was performed in 1X Tris-acetate EDTA 
(TAE) buffer (Appendix 7.3.7), at 100 V for 1 hour using a Bio-Rad Power Pac Basic (Bio-
Rad, USA). The gel was visualised over a UV trans-illuminator, and the linearised plasmid 
was excised and extracted from the gel using the GeneJet Gel Extraction Kit (Thermo 
Scientific, Lithuania) according to the protocol provided by the manufacturer (Appendix 
7.4.5). The eluted product was quantified using the Nanodrop ND-1000 spectrophotometer 
(Nanodrop Technologies, USA). 
For the each of the five CRISPR/Cas9 target sequences, a pair of complementary 
oligonucleotides were synthesised by Integrated DNA Technologies (IDT, USA). Each pair of 
oligonucleotides were composed of a 20 nucleotide guide sequence for their target and 
appropriate 5ʹ overhangs that allowed for sticky-end ligation into the BsmBI digested 
pcDNA.H1.sgRNA expression plasmid (Figure 4A). See Table 1 for the oligonucleotide 
sequences used. 
Each oligonucleotide pair was annealed and phosphorylated in individual reactions 
containing 1 µl dATP (10 mM stock concentration), 1 µl of each oligonucleotide (100 µM 
stock concentration), 1 µl 10X T4 Ligation Buffer (New England Biolabs, Germany) 
containing 500 mM Tris-HCl, 100 mM MgCl2, 10 mM ATP and 100 mM DTT (pH7.5 at 
25°C), 0.5 µl T4 polynucleotide kinase (New England Biolabs, Germany) and 6.5 µl of 
ddH2O. This was incubated in a Bio-Rad MJ Personal Thermal Cycler (Bio-Rad, USA) that 
was programmed to incubate the reaction at 37°C for 30 minutes, and then denature the 
oligonucleotides at 95°C for 5 minutes. After this, the thermal cycler was switched off and 
allowed to cool to room temperature for the complementary oligonucleotides to anneal. Each 
guide sequence duplex was then ligated into the linearised pcDNA.H1.sgRNA plasmid by 
mixing 1 µl of a 1:250 dilution of the annealed oligonucleotides with 50 ng of the plasmid 
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backbone in a 10 µl reaction containing 2.5 U T4 Ligase (Thermo Scientific, USA), ddH2O 
and 10X Ligation Buffer (Thermo Scientific, USA) which contains 400 mM Tris-HCl, 100 
mM MgCl2, 100 mM DTT and 5 mM ATP (pH 7.8 at 25°C). A control reaction, where the 
annealed oligonucleotide was substituted with ddH2O, was also included. The reactions were 
incubated at 22.5°C for 1 hour in the thermal cycler (Bio-Rad, USA). 2 µl of each ligation 
reaction was used to transform 100 µl of competent E. coli Stbl 3 cells as described in section 
2.2.1.1. Three colonies from each ampicillin-LB agar plate were picked, and each inoculated 
into 10 ml of ampicillin-LB broth. This was incubated for 14-16 hours at 37°C in a shaking 
incubator set at 180 rpm. Following this, the plasmid clones were extracted using the 
QIAprep Spin Miniprep kit according to the provided manufacturer’s protocol (Appendix 
7.4.2). The isolated DNA was quantified using the Nanodrop ND-1000 spectrophotometer 
(Nanodrop Technologies, USA) and each clone was sent for Sanger sequencing at Inqaba 
Biotech. For this purpose, primer U-90a, which annealed immediately upstream of the H1 
promoter was used to read the guide sequences (Table 1) (Figure 4B). Clones that showed the 
successful ligation of the correct guide sequence were prepared in bulk as described in 
section 2.2.1.1. 
Table 1: List of primer sequences used for sgRNA cloning 
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Primer Name Usage Sequence (5ʹ - 3ʹ)
sgRNA F1 224 F sgRNA guide cloning GATCCGAGTTTGTATTAAAAGGTAC
sgRNA F1 224 R sgRNA guide cloning AAACGTACCTTTTAATACAAACTCG
sgRNA F2 225 F sgRNA guide cloning GATCCATGTGTGACATGTTCTAATA
sgRNA F2 225 R sgRNA guide cloning AAACTATTAGAACATGTCACACATG
sgRNA F3 226 F sgRNA guide cloning GATCCGTTTGTATTAAAAGGTACTGG
sgRNA F3 226 R sgRNA guide cloning AAACCCAGTACCTTTTAATACAAACG
sgRNA R1 227 F sgRNA guide cloning GATCCGTGAATTAGCTGTATCGTCA
sgRNA R1 227 R sgRNA guide cloning AAACTGACGATACAGCTAATTCACG
sgRNA R2 228 F sgRNA guide cloning GATCCACAAGATTTACCTCTATTGT
sgRNA R2 228 R sgRNA guide cloning AAACACAATAGAGGTAAATCTTGTG
U-90a sgRNA sequencing TCCCCGAAAAGTGCCACCTGACG
 Figure 4: The cloning strategy of the guide sequence into the pcDNA.H1.sgRNA expression plasmid. 
(A) The design of a pair of complementary oligonucleotides that have a 20 nucleotide guide sequence (blue) and 
the respective 5ʹ overhangs (green and red). (B) A schematic of the pcDNA.H1.sgRNA expression plasmid. The 
expression plasmid is digested by the type II restriction enzyme BsmbI, to produce overhangs that facilitate the 
sticky-end ligation of the annealed oligonucleotide pairs. 
2.2.2 dsDNA donor cassette 
2.2.2.1 Amplification of the dsDNA donor components 
The dsDNA donor construct is composed of various DNA parts that were each isolated and 
amplified using polymerase chain reactions (PCRs). The construction of the dsDNA donor 
was done by assembling these DNA parts in two sequential overlap-extension PCRs. In this 
way, the large dsDNA donor construct was assembled very efficiently, without the need for 
!24
A
B
multiple cloning steps, and produced a seamless product. The primer sequences used are 
shown in Table 2 and the completed DNA fragment sequences are shown in Appendix 7.2.1. 
Enhanced Green Fluorescent Protein (eGFP) fragment (875 bp) 
The eGFP gene sequence was amplified from the pCI-NeoR-eGFP plasmid (Appendx 7.5.2). 
Three primers were designed to amplify the eGFP sequence and add overlapping sequences 
that would aid the subsequent assembly of the dsDNA donor. On the 5ʹ end of the eGFP 
fragment was an extension that encoded for half of the 2A self-cleaving peptide sequence. 
The 3ʹ end consisted of a synthetic PolyA tail and a complementary linker sequence to the 5ʹ 
KRAS homology arm. These features were added in two consecutive rounds of PCR (Figure 
5). The first round of PCR contained 10 µl of 2X Phusion Flash High-Fidelity PCR Master 
Mix (Thermo Scientific, USA), 1 µl of each eGFP F and eGFP R primer (10 µM stock 
concentration), 1 µl of the pCI-NeoR-eGFP plasmid (1 ng/µl stock concentration) and 7 µl 
ddH2O. Thermal cycling conditions were set so that the initial denaturation of 98°C lasted 10 
seconds, followed by 25 cycles of denaturation at 98°C for 1 second, annealing at 64.7°C for 
5 seconds, extension at 72°C for 15 seconds, and a final extension at 72°C for 1 minute. 2 µl 
of this reaction was mixed with 8 µl ddH2O and 2 µl 6X DNA Loading Dye (Thermo 
Scientific, USA). The DNA products were resolved on an ethidium bromide stained, 1% (w/
v) agarose gel. Electrophoresis was carried out in 1X TAE, at 75 V for 1 hour using a Bio-
Rad Power Pac Basic (Bio-Rad, USA). 5 µl of Kapa Universal Ladder (Kapa Biosystems, 
USA) was used as a size marker. The PCR product was then visualised using a Bio-Rad Gel 
Doc EZ imaging system (Bio-Rad, USA). The second round PCR was prepared in the same 
way as the first, except the primer set combination was changed to 1 µl of 5ʹHA F and 1 µl of 
eGFP R (10 µM stock concentration). The template used in this reaction was 1 µl of a 1:500 
dilution of the round 1 PCR. The cycling conditions remained the same, except the annealing 
temperature was increased to 70.4°C. Visualisation of this product was carried out in the 
same way as described for the round 1 reaction. The completed round 2 product was column 
purified with the GeneJet PCR Purification Kit (Thermo Scientific, Lithuania) according to 
the provided protocol (Appendix 7.4.6). The eluted DNA was quantified using the Nanodrop 
ND-1000 spectrophotometer (Nanodrop Technologies, USA). 
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 Figure 5: A schematic outlining the production of the eGFP fragment. eGFP was amplified from pCI-NeoR-
eGFP. A poly A tail and  overlapping linker sequences were added in two subsequent rounds of PCR. The linkers 
served to fuse this fragment with the upstream 5ʹHA and the downstream SV40-NeoR fragment. 
SV40-NeoR fragment (1 332 bp) 
Similarly, the SV40-NeoR gene sequence was amplified from the pCI-NeoR-eGFP plasmid 
(Figure 6). The forward primer was designed to prime to the 5ʹ end of the SV40 promoter 
upstream of the NeoR gene. This primer also provided an overlapping sequence into the 
KRAS reconstitution sequence (KRS) fragment (see section 2.2.2.1 - KRAS reconstitution 
sequence (KRS) fragment). The reverse primer bound to the 3ʹ end of the NeoR gene 
sequence and contained the second half of the 2A self-cleaving peptide sequence. The 
overlapping sequences of this 2A peptide was designed to serve as a linker between the 
SV40-NeoR and eGFP gene fragments, and allow for the expression of eGFP and NeoR from 
the single SV40 promoter. The amplification reaction was set up as described in section 
2.2.2.1 - eGFP fragment, but contained the SV40-NeoR F and SV40-NeoR R primers 
(10 µM stock concentration) instead. PCR cycling conditions were altered slightly and set so 
that the initial denaturation at 98°C lasted 10 seconds, followed by 25 cycles of denaturation 
at 98°C for 1 second, annealing and extension at 72°C for 20 seconds, and a final extension at 
72°C for 1 minute. The DNA was then visualised on an ethidium bromide stained agarose 
gel, column purified and quantified as described in section 2.2.2.1 - eGFP fragment.  
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Figure 6: A schematic outlining the production of the SV40-NeoR fragment. The SV40 promoter and the 
NeoR expression cassette was amplified from pCI-NeoR-eGFP. Terminal linker sequences were added by PCR 
for its fusion with the eGFP and KRS fragments. 
KRAS reconstitution sequence (KRS) fragment (131 bp) 
Two consecutive rounds of PCR were used to generate the KRS fragment (Figure 7). The first 
reaction involved the annealing and extension of two complementary oligonucleotides which 
contained the KRS. This was done by setting up a PCR with 10 µl of 2X Phusion Flash High-
Fidelity PCR Master Mix (Thermo Scientific, USA), 1 µl of each KRAS F and KRAS R1 
primer (10 µM stock concentration) and 8 µl ddH2O. Thermal cycling conditions were set so 
that the initial denaturation of 98°C lasted 10 seconds, followed by 25 cycles of denaturation 
at 98°C for 1 second, annealing at 54.7°C for 5 seconds, extension at 72°C for 3 seconds, and 
a final extension at 72°C for 1 minute. The product was subject to electrophoresis and 
visualisation as previously described in section 2.2.2.1 - eGFP fragment. The second round 
PCR was carried out in a similar manner as round 1. However, primer KRAS R2 (10 µM 
stock concentration) was used in place of KRAS R1, and 1 µl of a 1:500 dilution of the round 
1 reaction was used as the template. Cycling conditions were slightly altered, with the 
annealing temperature increased to 56°C. The completed fragment consisted of the KRS and 
was flanked by overlapping linker sequences that were complementary to the SV40-NeoR 
fragment and the 3ʹ KRAS homology arm. The product was visualised, column purified and 
quantified as previously described (see section 2.2.2.1 - eGFP fragment). 
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Figure 7: A schematic outlining the production of the KRS fragment. The KRS fragment was generated in 
two subsequent rounds of PCR. The first involved the primer annealing and extension of primer KRAS F and 
R1. A 3ʹ linker sequence was added in the second reaction for its fusion with the downstream 3ʹ HA. 
KRAS homology arms (5ʹ HA - 437 bp, 3ʹ HA 432 bp) 
Homology arms (HAs) that flanked the 5ʹ and 3ʹ DSBs were obtained by PCR from the 
genomic DNA (gDNA) of HEK 293 cells (Figure 8). HEK 293 cells were harvested and 
1 × 106 cells (as determined by cell counting described in section 2.1) were collected for 
gDNA extraction with the QIAamp DNA Mini Kit (Qiagen, Germany) by following the 
recommended protocol (Appendix 7.4.4). The gDNA was quantified using the Nanodrop 
ND-1000 spectrophotometer (Nanodrop Technologies, USA) and diluted to a concentration 
of 20 ng/µl. The 5ʹ HA was amplified with 10 µl of 2X Phusion Flash High-Fidelity PCR 
Master Mix (Thermo Scientific, USA), 1 µl of each 5ʹHA F2 and 3ʹHA R2 primer (10 µM 
stock concentration), 2.5 µl of gDNA (20 ng/µl stock concentration) and 5.5 µl ddH2O. 
Cycling conditions were set so that the initial denaturation of 98°C lasted 10 seconds, 
followed by 35 cycles of denaturation at 98°C for 1 second, annealing at 62.7°C for 5 
seconds, extension at 72°C for 7 seconds, and a final extension at 72°C for 1 minute. The 3ʹ 
HA was amplified in the same way, using the HA3ʹ F2 and HA3ʹ R2 primers (10 µM stock 
concentration) instead. The HAs were then visualised on an agarose gel, column purified and 
quantified and (see section 2.2.2.1 - eGFP fragment). 
Figure 8: A schematic of the 5ʹ and 3ʹ HAs. Each HA was amplified, with the illustrated primer pairs, from 
gDNA extracted from HEK 293 cells. 
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2.2.2.2 dsDNA donor assembly  
Three-way fusion of insertion DNA cassette (2 349 bp) 
The column purified fragments of the insertion cassette (eGFP fragment, SV40-NeoR 
fragment and KRS fragment) were pooled into a single reaction for the three-way fusion of 
the gene fragments by overlap extension PCR. This involved the complementary binding and 
extension of corresponding and overlapping linker sequences, that were added to the 
terminals of each fragment, and the subsequent fusion of all the gene fragments in the 
designed configuration, into one seamless product (Figure 9). This reaction contained 10 µl of 
2X Phusion Flash High-Fidelity PCR Master Mix (Thermo Scientific, USA), 1 µl of the 5ʹHA 
F and the KRAS R2 primers (10 µM stock concentration), equimolar amounts (28 fmol) of 
the eGFP fragment (16.5 ng), the SV40-NeoR fragment (25 ng) and the KRS fragment (3.5 
ng) and ddH2O to make up a final reaction volume of 20 µl. The amount of each fragment 
needed in the reaction was calculated by multiplying the molar mass of each fragment (length 
of fragment (bp) × 660 g/mol) by the molar concentration (28 fmol) needed. In order to 
ensure that the small KRAS reconstitution fragment (191 bp) was successfully incorporated 
into the construct, a control reaction was also setup. In this reaction, the KRS fragment was 
excluded from the reaction and the SV40-NeoR F primer (10 µM stock concentration) was 
used in place of the KRAS R2 primer. This produced a truncated fusion product that was 
compared to the full cassette. The reaction was subjected to the following cycle conditions: 
initial denaturation at 98°C for 10 seconds, followed by 35 cycles of denaturation at 98°C for 
1 second, annealing at 56°C for 5 seconds, extension at 72°C for 30 seconds, and a final 
extension at 72°C for 1 minute. The PCRs were visualised on an agarose gel to ensure 
successful assembly, after which the products were column purified and quantified (see 
section 2.2.2.1 - eGFP fragment). 
Homology arm extension (3 111 bp) 
The 5ʹ and 3ʹ homology arms were finally added to the terminals of the insertion DNA 
cassette through a subsequent overlap-extension PCR (Figure 9). A reaction composed of 
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15 µl of 2X Phusion Flash High-Fidelity PCR Master Mix (Thermo Scientific, USA), 1 µl of 
the 5ʹHA F2 and the 3ʹHA R2 primers (10 µM stock concentration), equimolar amounts of the 
insertion DNA cassette (30 ng), 5ʹ HA (5.5 ng) and 3ʹ HA (5.4 ng) and ddH2O to make up a 
final volume of 30 µl. The reaction was subjected to the following cycle conditions: initial 
denaturation at 98°C for 10 seconds, followed by 35 cycles of denaturation at 98°C for 1 
second, annealing at 60°C for 5 seconds, extension at 72°C for 45 seconds, and a final 
extension at 72°C for 1 minute. The full dsDNA donor was gel purified as described in 
section 2.2.1.2. 
 
Figure 9: The overlap extension PCR assembly strategy for the dsDNA donor construct. Each of the 
fragments, illustrated previously, were fused together by terminal complementary linker sequences, in two 
sequential reactions. In the first reaction, the insertion DNA cassette, which comprises of the expression 
construct and the KRAS reconstitution sequence, was assembled and amplified. The 5ʹ and 3ʹ HAs were 
subsequently added to the ends of this, by a second overlap extension PCR. 
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2.2.2.3 Blunt-end ligation of the dsDNA donor cassette into pJet 1.2/blunt Cloning Vector 
Ligation 
The completed dsDNA donor cassette was ligated into the pJet1.2/blunt Cloning Vector 
(Appendix 7.5.3) by blunt-end ligation, using the CloneJet PCR Cloning Kit (Thermo 
Scientific, USA). 150 ng of the dsDNA donor was ligated into 50 ng of the plasmid vector, in 
a reaction containing 10 µl of 2X Reaction Buffer (which contains 80 mM Tris-HCl, 20 mM 
MgCl2, 20 mM DTT and 1 mM ATP (pH 7.8 at 25°C), 2.5 U of T4 Ligase and ddH2O for a 
final reaction volume of 20 µl. The reaction was incubated at 22.5°C for 1 hour in the thermal 
cycler (Bio-Rad, USA). 15 µl of the ligation reaction was used to transform and plate 100 µl 
of competent E. coli Stbl3 cells as described in section 2.2.1.1.  
Colony PCR 
Four colonies from the ampicillin-LB agar plate were picked, and inoculated into 10 ml of 
ampicillin-LB broth. Before these were cultured, each of them were screened for the newly 
ligated construct by colony PCR. This involved dipping the picked colony into a PCR mix 
prior to inoculating into the broth. Each colony PCR reaction was prepared with 1µl of the 
pJet 1.2 forward sequencing primer and 1 µl of the pJet 1.2 reverse sequencing primer from 
the CloneJet PCR Cloning Kit (Thermo Scientific, USA) (10 µM stock concentration) (which 
each primed to the outside of the cloning site of the plasmid vector) (Table 2), 5 µl of 2X 
Phusion Flash High-Fidelity PCR Master Mix (Thermo Scientific, USA) and 3 µl of ddH2O. 
Thermal cycling conditions were set as follows: initial denaturation at 98°C for 10 seconds, 
followed by 30 cycles of denaturation at 98°C for 1 second, annealing at 60°C for 5 seconds, 
extension at 72°C for 45 seconds, and a final extension at 72°C for 1 minute. The PCRs were 
mixed with 2 µl 6X DNA Loading Dye (Thermo Scientific, USA) and subject to gel 
electrophoresis (see section 2.2.2.1 - eGFP fragment). Colonies that were positive for the 
dsDNA donor cassette product were cultured for 14-16 hours at 37°C in a shaking incubator 
set at 180 rpm. Following this, the plasmid DNA was extracted from these cultures and 
quantified as described in section 2.2.1.2. 
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Restriction digestion 
To further confirm that the plasmid clones were positive for the dsDNA donor, a restriction 
digest was carried out. 500 ng of each plasmid clone was digested with 10 U of BglII in 2 µl 
of Buffer O (Thermo Scientific, USA), which contains 50 mM Tris-HCl (pH 7.5 at 37°C), 
10 mM MgCl2, 100 mM NaCl and 0.1 mg/ml BSA, and 16 µl of ddH2O. This reaction was 
incubated for an hour at 37°C, after which the digested DNA was mixed with 4 µl 6X DNA 
Loading Dye (Thermo Scientific, USA) and resolved on an agarose gel (see section 2.2.2.1 - 
eGFP fragment). Plasmids containing the dsDNA donor (pJet-dsDNA donor) were digested 
such that the full dsDNA donor cassette was cut out of the plasmid. Positive clones were 
confirmed by Sanger sequencing, and prepared in bulk as described in section 2.2.1.1.  
The functionality of the expression cassette was tested by transfecting 2 µg of the plasmid 
into HEK 293 cells (see section 2.3.1) and monitoring the expression of eGFP (excitation at 
488 nm and emission at 509 nm) under an Olympus IX71 fluorescence microscope 
(Olympus, USA), 48 hours afterwards. pCI-NeoR-eGFP was used as a transfection control. 
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Table 2: List of primer sequences used for the production of the dsDNA donor 
2.3 Surveyor Assay 
The efficiency of each sgRNA to mediate a DNA DSB was assessed using the Surveyor 
Assay to measure the frequency of indel formation as a result of NHEJ-mediated DNA repair 
(Mussolino et al., 2011, Ran et al., 2013b). Briefly, the hybridisation of PCR amplicons from 
modified and unmodified KRAS alleles formed heteropduplexes that have base-pair 
mismatches at the DSB site as a result of indels that have formed from NHEJ repair. These 
heteroduplexes were digested by the mismatch-sensitive T7 endonuclease I (T7EI), and the 
ratio of digested products to undigested products was used to calculate the frequency of indel 
formation (Figure 11B). 
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Primer Name Usage Sequence (5ʹ - 3ʹ)
eGFP F eGFP fragment R1 TCAAGTTGGCGGGAGACGTCGAGTCCAACCCTGGGCCCATGGTGAGCAAG
GGCGAGGAGC
eGFP R eGFP fragment R1 CACACAAAAAACCAACACACAGATGTAATGAAAATAAAGATATTTTATTTCTAG
AGTATACGGACCGTTACTTG
5ʹHA F eGFP fragment R2, Fusion PCR 
R1
GTTTGTATTAAAAGGTACTGGTGGAGTATTTGATAGTGTATTAACCTTATCACA
CAAAAAACCAACACACAGATG
NeoR F SV40-NeoR fragment TAATGAAAATGTGACTATATTAGAACATGTCACACGCGCAGCACCATGGCCT
GAAATAAC
NeoR R SV40-NeoR fragment ACGTCTCCCGCCAACTTGAGAAGGTCAAAATTCAAAGTCTGTTTCACGAAG
AACTCGTCAAGAAGGCGATAGAAG
KRAS F KRS fragment R1 GTGTGACATGTTCTAATATAGTCACATTTTCATTATTTTTATTATAAGGCCTGCT
GAAAATGACTGAATATAAACTTGTGGTAGTTGGAG
KRAS R1 KRS fragment R1 GTCTACAAAATGATTCTGAATTAGCTGTATCGTCAAGGCACTCTTGCCTACGC
CAACAGCTCCAACTACCACAAGTTT
KRAS R2 KRS fragment R1, Fusion PCR 
R1
GCATATTAAAACAAGATTTACCTCTATTGTTGGATCATATTCGTCTACAAAATG
ATTCTG
5ʹHA F2 5ʹ HA, Fusion R2 TAGCTGTTGCATATTGACTTCTAACACTTAGAGG
5ʹHA R2 5ʹ HA ATAAGGTTAATACACTATCAAATACTCCACCAGTACC
3ʹHA F2 3ʹ HA AATCATTTTGTGGACGAATATGATCCCACAAT
3ʹHA R2 3ʹ HA, Fusion PCR R2 CCATCAAACAATTATATTTCACTAGTACAATTAAATCTAACCTTT
pJet 1.2 F dsDNA donor colony PCR CGACTCACTATAGGGAGAGCGGC
pJet 1.2 R dsDNA donor colony PCR AAGAACATCGATTTTCCATGGCAG
2.3.1 Transfection 
24 hours prior to transfection, 1.5 × 106 HEK 293 cells were harvested (see section 2.1) and 
seeded into a 6-well plate (250 000 cells/well), with 2 ml of complete DMEM per well. The 
total number of cells harvested was adjusted according to the number of transfection 
conditions being carried out. The next day, before commencing with the transfection 
procedure, the cell culture medium was renewed with 2 ml of fresh complete DMEM. All the 
plasmids used for transfection were prepared in bulk (see section 2.2.1.1) and normalised to a 
concentration of 1 µg/µl. In each transfection, 2 µg of the sgRNA expression plasmid 
(pcDNA-sgRNA KRAS 224 - 228) was mixed with 2 µg of the Cas9 expression plasmid 
(pX330 - Appendix 7.5.4) and 100 µl of serum-free DMEM lacking antibiotics in a 1.5 ml 
microcentrifuge tube. To this, 12 µl of branched polyethylenimine (PEI) (Sigma Aldrich, 
USA) (1 µg/ml stock concentration) was added, and each tube was immediately pulse-
vortexed at a medium intensity 15 times, for 1 second each. This mixture was then incubated 
at room temperature (~25°C) for exactly 10 minutes. Following this, 600 µl of complete 
DMEM was added, and this transfection mixture was added, in a drop-wise manner, to a well 
containing HEK 293 cells. The 6-well plate was then gently rocked before it was placed back 
into the cell culture incubator. After 3 hours, an additional 2 ml of complete DMEM was 
added to each well of transfected cells. Negative controls for this assay included transfections 
with the pX330 plasmid only and a mock transfection with ddH2O. In order to monitor 
transfection efficiency, a transfection with pCI-NeoR-eGFP was also carried out. 
2.3.2 gDNA extraction 
The transfection efficiency was assessed by visualising the expression of eGFP (at 488 nm) in 
the cells transfected with pCI-NeoR-eGFP. These cells were monitored 48 hours post-
transfection using an Olympus IX71 fluorescence microscope (Olympus, USA). The 
transfected cells in each well were then harvested by washing the cells with 2 ml of 1X PBS 
(Appendix 7.3.10), followed by trypsinisation with 1 ml Trypsin-EDTA (Hyclone, USA). The 
cells were incubated for 2-3 minutes at 37°C, before 500 µl of complete DMEM was added to 
neutralise the trypsin. The cell suspension was then transferred to a 1.5 ml microcentrifuge 
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tube and the cells were collected by centrifugation at 260×g for 5 minutes (Eppendorf 
Centrifuge 5402, Germany). The supernatant was then discarded, and the pellet was 
resuspended in 1 ml of 1X PBS and centrifuged again at 260×g for 5 minutes. This wash step 
was repeated. The final cell pellet was resuspended in 200 µl of 1X PBS and the gDNA was 
extracted from these cells using the QIAamp DNA Mini Kit (Qiagen, Germany) and the 
manufacturer’s recommended protocol (Appendix 7.4.4). The extracted gDNA samples were 
quantified using the Nanodrop ND-1000 (Nanodrop Technologies, USA) and each 
normalised to a working concentration of 20 ng/µl.  
2.3.3 PCR and heteroduplex formation 
The CRISPR/Cas9 cleavage regions of the KRAS gene were amplified using PCR. Two sets 
of primers were designed to amplify the two cleavage regions. The first set amplified the 5ʹ 
cleavage region (5ʹ Surveyor F and 5ʹ Surveyor R) (361 bp product), whereas the second set 
amplified the 3ʹ cleavage region (3ʹ Surveyor F and 3ʹ Surveyor R) (346 bp product) of the 
KRAS gene (see Table 3 for primer sequences). In each PCR, 1 µl of the appropriate forward 
and reverse Surveyor primer set (10 µM stock concentration) was added to 5 µl of 2X 
Phusion Flash High-Fidelity PCR Master Mix (Thermo Scientific, USA), 2.5 µl of gDNA and 
0.5 µl of ddH2O. Thermal cycling conditions were set as follows: initial denaturation at 98°C 
for 10 seconds, followed by 35 cycles of denaturation at 98°C for 1 second, annealing at 
69.8°C for the 5ʹ cleavage primers) and 65.8°C for the 3ʹ cleavage primers, for 5 seconds, 
extension at 72°C for 6 seconds and a final extension at 72°C for 1 minute. For each 
transfection condition, the PCR was setup and carried out in triplicate. Each triplicate 
reaction set was then pooled together and 2 µl of this was visualised on an agarose gel (see 
section 2.2.2.1- eGFP fragment). The PCR products were then column purified and 
quantified as described in section 2.2.2.1 - eGFP fragment. Each of the eluted PCR products 
were then normalised to a concentration of 30 ng/µl. 
For each PCR amplicon, 600 ng of DNA was added to 3 µl of 10X DreamTaq Buffer 
(Thermo Scientific, USA), which contains 750 mM Tris-HCl, 200 mM (NH4)2SO4, 0.1% 
(v/v) Tween 20 and 20 mM MgCl2, and 7 µl of ddH2O. The DNA duplexes were denatured by 
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heating to 95°C for 10 minutes in the thermal cycler (Bio-Rad, USA). After this, the machine 
was switched off and allowed to cool to room temperature, with the lid closed, to allow for 
the DNA to rehybridise and form heteroduplexes.  
2.3.4 Heteropduplex digestion and polyacrylamide gel electrophoresis (PAGE) 
150 ng of each heteroduplex product was digested by the mismatch-sensitive T7E1 (New 
England Biolabs, Germany). This was done in a reaction that contained 3 U of T7EI, 1 µl of 
NEB Buffer 2 (New England Biolabs, Germany), which was made up of 500 mM NaCl, 100 
mM Tris-HCl, 100 mM MgCl2 and 10 mM DTT (pH 7.9 at 25°C), and 1.2 µl of ddH2O. The 
digestion reaction was incubated at 37°C for 15 minutes. 
In the meantime, an 8% polyacrylamide gel was prepared. The 30% (w/v) polyacrylamide 
solution was prepared by dissolving 29 g of acrylamide (Bio-Rad, USA) and 1 g of 
bisacrylamide (Promega, USA) (29:1) in 1X Tris-borate EDTA (TBE) buffer (Appendix 
7.3.8) to a final volume of 100 ml. The polyacrylamide gel was made by diluting 3.2 ml of 
the 30% polyacrylamide solution with 8.8 ml of 1X TBE, and catalysing its polymerisation 
by adding 200 µl of 10% ammonium persulphate (APS) (SaarChem, South Africa) and 10 µl 
of tetramethylethylenediamine (TEMED) (Sigma Aldrich, USA). This mixture was solidified 
between two glass plates, separated by a 15 well, 1.5 mm spacer comb (Bio-Rad Mini 
Protean Tetra system, USA). Before being loaded, the gel cast cassette was submerged in 1X 
TBE. The comb was then carefully removed and the wells were flushed out with a 1 ml 
pipette. Each T7EI digestion reaction was then mixed with 2 µl of 6X DNA Loading Dye and 
loaded into the gel. 2 µl of the GeneRuler 50 bp DNA Ladder (Thermo Scientific, USA) was 
used as a size marker. The gel was then subject to electrophoresis at 55 V (E-C Apparatus 
Corporation, USA) for 2.5 hours at 4°C. The polyacrylamide gel was then carefully removed 
from the gel cast and placed in 100 ml TBE buffer containing 10 µl of SYBR Green I Nucleic 
Acid Gel Stain (Invitrogen, USA). The gel was stained for 15 minutes while being gently 
rocked (40 rpm). The gel was then imaged using the Bio-Rad Gel doc EZ Imager system 
(Bio-Rad, USA). 
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2.3.5 Analysis 
The gels of the Surveyor Assay were analysed using ImageLab (Bio-Rad, USA). A standard 
curve for each gel was created by the software, where the banding intensity of each band of 
the DNA ladder was correlated to its prescribed mass, as indicated by the manufacturer. This 
was used to quantify each of the bands, on the basis of band intensity, that resulted from the 
T7EI digestion of the heteroduplexes. The efficiency of target cleavage was then calculated 
using the following formula (Ran et al., 2013b): 
  
The two best sgRNAs (one that cleaved in the 5ʹ cleavage region and one that cleaved in the 
3ʹ cleavage region) which showed the highest cleavage efficiency were chosen to be used in 
the subsequent experiments. 
Table 3: List of primer sequences used for the testing of the sgRNAs 
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Primer Name Usage Sequence (5ʹ - 3ʹ)
5ʹ Surveyor F Surveyor assay, micro-deletion 
detection, RFLP
CGCAGAACAGCAGTCTGGC
5ʹ Surveyor R Surveyor assay CTACGCCACCAGCTCCAAC
3ʹ Surveyor F Surveyor assay AAGGCCTGCTGAAAATGACTG
3ʹ Surveyor R Surveyor assay, micro-deletion 
detection, RFLP
GCACAGAGAGTGAACATCATGG
2.4 Micro-deletion detection 
To detect the repair of two simultaneous DSBs (one 5ʹ cleavage and one 3ʹ cleavage), a PCR 
using primers that spanned across the repair junction was carried out (650 bp product). HEK 
293 cells were transfected in the same way as described in section 2.3.1. However, the 
transfection for the dual cleavage contained 2 µg of the 5ʹ cleavage pcDNA-sgRNA KRAS 
plasmid, 2 µg of the 3ʹ cleavage pcDNA-sgRNA KRAS plasmid and 2 µg of pX330. Control 
transfections contained 2 µg of either the 5ʹ or 3ʹ sgRNA expression plasmid and 2 µg of 
pX330. A mock transfection was also included. After 48 hours, the transfected cells were 
harvested and the gDNA extracted (see section 2.3.1 and 2.3.2). The gDNA was normalised 
to 20 µg/µl, of which 2.5 µl was added to 5 µl of 2X Phusion Flash High-Fidelity PCR Master 
Mix (Thermo Scientific, USA), 1 µl of 5ʹ Surveyor F (10 µM stock concentration), 1 µl of 3ʹ 
Surveyor R (10 µM stock concentration) and 0.5 µl of ddH2O. The PCRs underwent the 
following thermal cycling conditions: initial denaturation at 98°C for 10 seconds, followed by 
35 cycles of denaturation at 98°C for 1 second, annealing at 65.4°C for 5 seconds, extension 
at 72°C for 10 seconds and a final extension at 72°C for 1 minute. The PCR products were 
then visualised on an agarose gel as described in section 2.2.2.1- eGFP fragment. 
2.5 Assessing HDR efficiency with ssODNs 
The CRISPR/Cas9-mediated DSBs and the micro-deletion were repaired using short 90-mer 
ssODNs synthesised by IDT. Each of these ssODN repair templates contained two homology 
arms of 42 nucleotides each. In between the two arms, was the sequence for the EcoRI 
restriction enzyme recognition site that was designed to be integrated into the repair site by 
HDR. Three ssODN repair templates were used to assess the HDR of a 5ʹ DSB, a 3ʹ DSB and 
a micro-deletion that resulted from simultaneous 5ʹ and 3ʹ cleavages. The ssODN sequences 
are as follows: 
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Homology arms are shown in black, the EcoRI restriction site in green. 
> F1 ssODN 
TTGAAATAATTTTTCATATAAAGGTGAGTTTGTATTAAAAGGGAATTCTACTGGTGGAGTATTTGATA
GTGTATTAACCTTATGTGTGAC 
>R2 ssODN 
CAGCTAATTCAGAATCATTTTGTGGACGAATATGATCCAACAGAATTCATAGAGGTAAATCTTGTTTT
AATATGCATATTACTGGTGCAG 
>F1+R2 SSODN 
TTGAAATAATTTTTCATATAAAGGTGAGTTTGTATTAAAAGGGAATTCATAGAGGTAAATCTTGTTTTA
ATATGCATATTACTGGTGCAG 
HEK 293 cells were harvested and seeded into 6-well plates as described in section 2.3.1. The 
cells in each well were transfected with 2 µg of the chosen pcDNA-sgRNA KRAS expression 
plasmid, 2 µg of pX330 and 2 µl of the of the appropriate ssODN repair template (100 µM 
stock concentration) (see section 2.3.1) (see Supplementary figure 1 for ssODN dosage 
optimisation). For the micro-deletion, 2 µg of each pcDNA-sgRNA KRAS plasmid was used 
in a single transfection, for a total of 4 µg of sgRNA expression plasmids with 2 µg of pX330 
and 2 µl of the of the appropriate ssODN repair template (100 µM stock concentration). 
Control transfections included the sgRNA expression plasmids and pX330 without the 
ssODN repair template, or the ssODN repair template only. After 72 hours, the gDNA was 
extracted from these transfected cells and adjusted to 20 ng/µl, as described in section 2.3.2. 
The repaired KRAS locus was amplified using PCR, exactly as described in section 2.4. The 
PCR products were visualised on an agarose gel, column purified and quantified as 
previously outlined in section 2.2.2.1- eGFP fragment. Each sample of purified PCR product 
was diluted to 30 ng/µl, and was subject to a restriction digestion reaction containing 300 ng 
of DNA, 2µl of Buffer O (Thermo Scientific, USA), which contains 50 mM Tris-HCl (pH 7.5 
at 37°C), 10 mM MgCl2, 100 mM NaCl and 0.1 mg/ml BSA, 10 U of EcoRI (10 U/µl stock 
concentration) (Thermo Scientific, USA) and 7 µl of ddH2O. This was digested for 1 hour at 
37°C before the products were resolved and visualised on an 8% polyacrylamide gel as 
described in section 2.3.4. HDR efficiency was calculated with the same formula that is 
described in section 2.3.5. 
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2.6 Testing the “dual cut” strategy for the production of G>T KRAS mutants 
qPCR was used to quantify the efficiency of the CRISPR/Cas9-mediated integration of the 
dsDNA donor using the “dual cut” strategy. This involved the simultaneous induction of a 5ʹ 
and 3ʹ DSB as described in Figure 14. 
2.6.1 Linear dsDNA donor preparation 
A linearised form of the dsDNA donor was prepared for transfection for the dsDNA donor 
repair experiments. This was done by PCR amplification of the donor cassette from the pJet-
dsDNA donor plasmid, which was constructed and validated in section 2.2.2. The linear 
dsDNA donor was generated in a PCR which contained 25 µl of 2X Phusion Flash High-
Fidelity PCR Master Mix (Thermo Scientific, USA), 1 µl of 5ʹHA F2 (10 µM stock 
concentration), 1 µl of 3ʹHA R2 (10 µM stock concentration), 1 µl of pJet-dsDNA donor (25 
ng/µl stock concentration) and 22 µl of ddH2O. The thermal cycler (Bio-Rad, USA) was 
programmed to undergo an initial denaturation at 98°C for 10 seconds, followed by 35 cycles 
of denaturation at 98°C for 1 second, annealing at 62.7°C for 5 seconds, extension at 72°C 
for 45 seconds and a final extension at 72°C for 1 minute. Four identical reactions were 
prepared to generate enough linear dsDNA donor for a single experiment. The linear dsDNA 
donor product was column purified and quantified according to section 2.2.2.1 - eGFP 
fragment. 
2.6.2 gDNA template preparation 
HEK 293 cells were transfected in a 6-well plate (as described in section 2.3.1), with 2 µg of 
the appropriate pcDNA-sgRNA KRAS plasmid (2 µg of each pcDNA-sgRNA KRAS plasmid 
for the double cut), 2 µg of pX330 and 1 µg of the purified linear dsDNA donor PCR product. 
Two negative control transfections were included. The first of these contained 2 µg of the 
empty pcDNA.H1.sgRNA plasmid, 2 µg of pX330 and 1 µg of the linear dsDNA donor. The 
second control transfection contained 2 µg of each of the pcDNA-sgRNA KRAS plasmids, 2 
µg of pX330 and 1 µg of a mock donor. 72 hours post-transfection, half of the transfected 
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cells in each well were harvested for gDNA extraction as described in section 2.3.2. The 
gDNA was quantified and normalised to 16.5 ng/µl. 
The remaining cells were placed back into their wells, and supplemented with 2 ml of 
complete DMEM. These were cultured for another 11 days to dilute out exogenous episomal 
DNA, while maintaining recombinant cells. When the cells became confluent, the cell culture 
medium would be discarded and the cells were washed with 2 ml 1X PBS. Following this, the 
cells were detached by incubating them for 3 minutes at 37°C in 1 ml of Trypsin EDTA 
(Hyclone, USA). 1 ml of complete DMEM was added to neutralise the trypsin. The cell 
suspension was then thoroughly mixed by aspirating with a 1 ml pipette. 1 ml of this cell 
suspension was then discarded. The remaining cells were supplemented with 2 ml of 
complete DMEM and returned to the cell culture incubator. 14 days post-transfection, the 
HEK 293 cells were harvested and the gDNA was extracted from these cells as described 
above. 
2.6.3 Quantitative real-time PCR (qPCR) 
Four primer sets were designed for this experiment, using the NCBI Primer-BLAST tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The primer sequences are shown in Table 
4. Primer set A spanned the 5ʹ cleavage-repair junction, with the forward primer binding to a 
flanking endogenous KRAS sequence and the reverse primer binding to the end of the eGFP 
coding sequence. This allowed for the quantification of dsDNA donor constructs that were 
successfully integrated into the KRAS gene target site. Primer set B primed to the NeoR 
coding sequence, which was present in the dsDNA donor and the sgRNA expression 
plasmids. The readout from this primer set served as an indication of the levels of exogenous 
episomal DNA over time. Primer set C primed to the KRS of the dsDNA donor. The forward 
primer is allele specific to the G>T point mutation, resulting in amplification from the 
dsDNA donor only, and not the WT allele. Primer set D was designed to measure the total 
KRAS DNA of the target region, as it primes to a region that is slightly downstream of the 
cleavage target sites. β-actin was used as a reference gene. Because the qPCR was performed 
on gDNA, reference gene considerations were not heavily scrutinised as it was assumed that 
!41
each cell will have the same number of β-actin gene copies. Each of these primer sets were 
optimised at different annealing temperatures (see Supplementary figure 2), and the reactions 
were all checked for product specificity by melt curve analysis and agarose gel 
electrophoresis (Supplementary figure 3).  
Table 4: List of primer sequences used for qPCR 
To each qPCR, 5 µl of 2X SYBR Green PCR Mastermix (Applied Biosystems, USA), 1 µl of 
the forward primer (2 µM stock concentration), 1 µl of the reverse primer (2µM stock 
concentration) and 3 µl of the gDNA template (16.5 ng/µl stock concentration) was added. 
No template control reactions were also included. These were setup in a 96-well PCR plate, 
which was centrifuged at 865×g for 3 minutes (Boeco U-320, Germany), before being loaded 
into an Applied Biosystems 7500 RT PCR System, USA. These reactions then underwent an 
initial hold stage at 50°C for 2 minutes, followed by denaturation at 95°C for 10 minutes and 
50 cycles of denaturation at 95°C for 15 seconds and annealing and extending at 55°C (for 
primer set A, B and Beta-actin) or 60°C (for primer set C and D) for 1 minute. An inter-plate 
calibrator (IPC) reaction was included for each primer set so that any technical variations 
between the 72 hours and 14 days samples could be controlled for. The IPC template mixture 
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Primer Name Usage Sequence (5ʹ - 3ʹ)
Primer set A F qPCR CCAAGAGAACTACTGCCATGATGC
Primer set A R qPCR GCATGGACGAGCTGTACAAGT
Primer set B F qPCR TGATATTCGGCAAGCAGGCA
Primer set B R qPCR GACCACCAAGCGAAACATCG
Primer set C F qPCR AACTTGTGGTAGTTGGAGCTGT
Primer set C R qPCR GGTCCTGCACCAGTAATATGCA
Primer set D F qPCR TTATTTGGGCGGAAGGCTGA
Primer set D R qPCR GTCAGGGACCGTCAGTTTCA
β-actin F qPCR ACCAACTGGGACGACATGGAGAAA
β-actin R qPCR TAGCACAGCCTGGATAGCAACGTA
was made up by adding 10 µl of each gDNA sample (16 ng/µl stock concentration) obtained 
72 hours post-transfection. 3 µl of this was used as a template in each IPC control reaction. 
2.6.4 Analysis  
The data of each primer set were mathematically corrected according to the changes seen in 
the threshold (Cq) values of the corresponding IPC reactions by performing the following 
function: 
 
The corrected data generated from the qPCR experiments were analysed and represented as a 
fold change relative to β-actin. Briefly, this involved normalising the Cq values for each 
sample to that of β-actin by subtracting the β-actin Cq from the Cq value of the 
corresponding sample, to obtain a ∆Cq value. To calculate the fold change, the following 
transformation was performed: 2∆Cq. This was done according to “Guide to Performing 
Relative Quantitation of Gene Expression Using Real-Time Quantitative PCR” (Applied 
Biosystems, USA). 
2.7 Statistical Analyses 
Statistical analysis was carried out using the online QuickCalcs tool provided by GraphPad 
(http://www.graphpad.com/quickcalcs/). Student’s t-tests were performed on the data from 
the Surveyor Assay and HDR efficiency experiment. Pearson’s correlation coefficient was 
used to determine the strength of linear correlations. The F-test was used to determine the 
statistical significance of these linear regressions. 
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3. Results 
3.1 Cloning of sgRNA expression plasmids 
The online CRISPR tool identified 14 NGG PAM sites around the G>T KRAS mutation 
hotspot. Each of these potential sgRNA target sites were ranked according to a score that was 
inversely correlated to the number of predicted off-target sites within the human genome. The 
search area for these potential sgRNA target sites was limited to 250 bp around the mutation 
point (125 bp in each direction) so that the returned target sites were within very close 
proximity to each other. This ensured that variations associated with markedly different 
genomic target sites were eliminated, allowing for the effect of the guide sequence 
composition on sgRNA activity to be examined more accurately. Furthermore, in order to edit 
the point mutation, the HDR-stimulating DSBs needed to be sufficiently close to the mutation 
site for it to be effective. A total of five sgRNA guide sequences were chosen on the basis of 
the returned score of each target site identified by the online CRISPR tool, as well as the 
sequence requirements for the H1 Pol-III promoter transcriptional start site (Figure 10A). 
Target sequences that started (at the 5ʹ end) with a guanine or an adenosine were selected for 
optimal H1 Pol-III-mediated sgRNA expression. Therefore, the optimal sgRNA guide 
sequences that were chosen to target this region of the KRAS gene adhered to the formula 
G/A (19-20N) NGG. Three of these optimal targets sites were upstream of the G>T mutation 
(5ʹ cleavage) and the remaining two were downstream of the mutation (3ʹ cleavage). This 
allowed for different sites around the mutation to be targeted, and for potential gene deletions 
that span the mutation site to be induced. The guide sequence for each target site was ligated 
into the pcDNA.H1.sgRNA expression plasmid as an annealed pair of complementary 
oligonucleotides. This process resulted in the insertion of a 20 bp guide sequence 
immediately downstream of the H1 Pol-III promoter, which was designed to drive the 
expression of the inserted guide sequence and the RNA scaffold, as a single chimeric sgRNA 
molecule. Sanger sequencing was used to confirm the successful insertion of the guide 
sequences into the plasmid vector. This was done with a primer that bound upstream of the 
H1 promoter, allowing for the forward read into the ligated guide sequence. The sequence 
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readouts showed that all the KRAS target guide sequences were successfully ligated into the 
sgRNA expression vector (Figure 10B). 
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Figure 10: The design and screening of the sgRNA constructs. (A) A schematic showing the sgRNA target 
sites around the G>T mutation hotspot on the KRAS gene. Three of the sgRNAs targeted a region upstream of 
this hotspot (in the 5ʹ cleavage region - red) and the remaining two, a region downstream of the hotspot (in the 3ʹ 
cleavage region - blue). The coverage of these five sgRNAs was not more than 250 bp of the gene sequence. 
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The red and blue lines indicate the target sequences for the 5ʹ and 3ʹ sgRNAs, respectively. The pink line 
corresponds with the PAM tri-nucleotide recognition site. The arrowhead shows the cleavage site. The guide 
sequences of the three 5ʹ sgRNAs were complementary to the bottom strand, and the two of the 3ʹ sgRNAs to 
the top strand. (B) A schematic showing the sgRNA expression construct. Sanger sequencing was used to check 
the sequence of this construct in potentially positive clones. A forward primer that bound upstream of the H1 
promoter was used. The chromatograms show the 5ʹ sequence of the H1 promoter (green), the full guide 
sequence (blue) and the 3ʹ end of the RNA scaffold (red) for each of the five sgRNA constructs, which all 
correspond to their target sites. 
3.2 Surveyor Assay 
In order to test the functionality of each sgRNA, the Surveyor Assay was used to measure the 
frequency of indel formation as a result of NHEJ repair of CRISPR/Cas9-mediated DSBs 
(Mussolino et al., 2011, Ran et al., 2013b). This was done in the absence of an exogenous 
homologous repair template. The Surveyor Assay provides a simple method to detect any 
indel formation as a result of NHEJ repair of a DSB and give a readout of whether the DNA 
was cleaved or not at each sgRNA target site (Figure 11A and B). It is able to do this from a 
population of diverse, stochastically-formed indels, compared to other well known 
polymorphism detection assays, such as single-strand conformation polymorphism analysis, 
which is better suited for the detection of and comparison between single polymorphic 
species (Orita et al., 1989). Furthermore, because the Surveyor Assay is able to clearly 
distinguish cleaved DNA products from uncleaved, irrespective of the type of indel formed, 
semi-quantitative data can be obtained from this assay, providing information on the cleavage 
efficiency mediated by each sgRNA. 
The presence of digested PCR products suggested that the CRISPR/Cas9 system components 
were being successfully expressed and translated, and were functional in targeting the KRAS 
locus. Gel electrophoresis of the 5ʹ and 3ʹ cleavage region amplicons showed that the PCRs 
were successful, producing very specific products of 361 and 346 bp in size, respectively 
(Figure 11C). The specificity of the PCR products was particularly important for the Surveyor 
Assay, as any non-specific species would have formed heteroduplexes that contributed to 
background noise and possibly false positives. Subsequent digestion of these heteroduplexes 
with the T7EI nuclease revealed that all the sgRNAs were functional. This was seen on the 
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polyacrylamide gel as the typical banding pattern of a single restriction digest of PCR 
products. Digestion of the 5ʹ cleavage region heteroduplexes produced fragments of 224 and 
137 bp for sgRNA F1 224, 274 and 87 bp for sgRNA F2 225 and 227 and 134 bp for sgRNA 
F3 226. The digestion of the 3ʹ cleavage region heteroduplexes generated fragments of 274 
and 72 bp for sgRNA R1 227, and fragments of 227 and 119 bp for sgRNA R2 228. Controls 
in which pX330 was transfected into the cells without an accompanying sgRNA expression 
construct showed no targeted cleavage. Similarly, a transfection with pCI-NeoR-eGFP (to 
monitor transfection efficiency) and a mock transfection showed no specifically digested 
products either (Figure 11D). This confirmed that the CRISPR/Cas9 system was able to 
introduce targeted DSBs in the KRAS gene locus and stimulate the NHEJ DNA repair 
pathway. The cleavage efficiency of each sgRNA was calculated (see section 2.3.5) from 
three biologically independent repeats and showed that the sgRNAs functioned at varying 
efficiencies (Figure 11E). sgRNA F1 224 was the most efficient at cutting in the 5ʹ cleavage 
region, with an average efficiency of 6.01%. sgRNA R2 228 showed a cleavage efficiency of 
2.74%, the highest out of the two 3ʹ cleavage region targeting sgRNAs. Interestingly, sgRNA 
F1 224 performed significantly better than the other sgRNAs, even though they all target 
sequences within the same region. 
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 Figure 11: Functional assessment of the KRAS targeting sgRNAs with the Surveyor Assay. (A) A schematic 
of the KRAS gene locus chosen for CRISPR/Cas9 targeting. The cleavage site of each sgRNA is depicted as an 
arrowhead. The two primer sets used to amplify the 5ʹ and 3ʹ cleavage region are also shown, in red and blue, 
respectively. (B) An outline of the Surveyor Assay. (C) An agarose gel showing the PCR products amplified 
from the 5ʹ (361 bp) and the 3ʹ (346 bp) cleavage regions of the KRAS gene. (D) A polyacrylamide gel showing 
the heteroduplexes after being digested with the mismatch sensitive T7EI nuclease. The upper bands represents 
PCR products from unmodified alleles, with the lower, digested bands from alleles that have experienced a DSB 
and subsequent NHEJ repair. Cells transfected with pX330 only (Cas9), pCI-NeoR-eGFP (eGFP) or water 
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(mock) served as controls. For each sgRNA the percentage of indel formation was calculated after densitometric 
quantification of the bands (E) The percentage of indel formation mediated by each of the sgRNAs from a 
triplicate experiment (mean±SD, *p<0.05, **p<0.01, unpaired Student’s t-test). 
3.3 Micro-deletion detection 
To demonstrate the use of the CRISPR/Cas9 system for gene deletions, sgRNA F1 224 and 
sgRNA R2 228 were used to introduce simultaneous DSBs in the 5ʹ and 3ʹ cleavage regions, 
respectively. It was expected that two concurrent DSBs at the target sites would result in the 
deletion of the region in between the two cuts. Because this was done in the absence of an 
exogenous repair template, the repair of the excised DNA should have occurred by NHEJ 
repair, whereby the outer ends of the broken DNA were re-ligated together. PCR across the 
deletion junction was used to detect alleles that had undergone the deletion event. Alleles that 
had experienced a micro-deletion would produce PCR amplicons that would reflect this, as 
they were predicted to be smaller in size compared to that of the WT alleles (Figure 12A). 
Visualisation of the PCR products on an agarose gel showed that when sgRNA F1 224 and 
R2 228 were applied simultaneously, a micro-deletion of 199 bp in the KRAS gene was 
introduced. Amplification from the deletion alleles generated a 451 bp product. This was 
smaller than the 650 bp product, which was amplified from the WT allele of cells that 
underwent a mock transfection. A product of the same size was observed when single DSBs 
were introduced, indicating that the repair of individual DSBs was not sufficient to stimulate 
gene deletion. This demonstrated that sgRNA F1 224 and sgRNA R2 228 were able to 
function concurrently to introduce two simultaneous DSBs, which generated a specific 
deletion in the KRAS gene (Figure 12B). Furthermore, this highlights the ability of the 
CRISPR/Cas9 system to successfully mediate targeted gene deletions, which is a useful 
function for genome engineering applications. 
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 Figure 12: PCR detection of CRISPR/Cas9 mediated micro-deletions. (A) A schematic showing the deleted 
199 bp sequence from the KRAS gene when sgRNA F1 224 and R2 228 were applied simultaneously to generate 
a double cut. This micro-deletion was detected by PCR amplification of this cleavage junction with the 
illustrated primers (B) An agarose gel showing the PCR products amplified from KRAS alleles that have 
undergone a micro-deletion, which was absent when only single DSBs are applied. Cells transfected with water 
(mock) produced PCR products from WT alleles only, which served as a comparative control. 
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3.4 HDR efficiency with ssODNs 
The results above show that the CRISPR/Cas9 system is able to successfully stimulate the 
NHEJ repair pathway when DSBs are introduced in the absence of an exogenous homologous 
repair template. This is useful in mutating genes through the resultant indels or gene deletions 
formed. However, for the precise targeted modification of genes, the CRISPR/Cas9 system 
needs to be able to stimulate the HDR pathway for the repair of DSBs according to specific 
repair templates. ssODNs have been shown to be able to seamlessly repair and modify 
targeted single DSB sites via HDR. Based on the optimal architecture outlined by Church et 
al., ssODNs harbouring the EcoRI restriction site were designed to be homologous to the top-
strand of the KRAS target region and serve as repair templates of individual sgRNA F1 224 
and R2 228 DSBs, as well as the previously described micro-deletion (Figure 13A) (Yang et 
al., 2013). The ability of the CRISPR/Cas9 system to stimulate the HDR of this targeted DNA 
damage, according to the ssODN templates, was assessed by RFLP analysis. It was expected 
that the individual DSBs and the micro-deletion would be repaired according to the 
homologous ssODN template, resulting in the integration of the EcoRI recognition sequence 
into the repair site. Digestion of PCR products amplified from this gene region, with EcoRI, 
would reveal the newly introduced restriction site, serving as an indicator for CRISPR/Cas9 
stimulated site-specific HDR. 
The repair region was successfully amplified in each transfection condition. WT alleles or 
alleles of repaired single DSB sites yielded a 650 bp long product. A 451 bp product was 
observed for the repair of the micro-deletion event. It is worth noting that the addition of the 
F1+R2 ssODN for the repair of the micro-deletion, seemed to stimulate gene deletion. This 
can be seen by the abundance of the deletion PCR product when the two sgRNAs were 
applied with the F1+R2 ssODN, compared to when the micro-deletion was induced in the 
absence of the F1+R2 ssODN repair template (Figure 13B). Densitometry of these PCR 
product bands showed that the micro-deletion occurred in approximately 53.2% of the 
amplified alleles when the F1+R2 ssODN was included. This only occurred in about 4.3% of 
the alleles when the F1+R2 ssODN was excluded. EcoRI digestion of these PCR amplicons 
revealed that both the individual DSBs as well as the micro-deletion were able to stimulate 
!52
HDR (Figure 13C). The repair of the micro-deletion produced fragments of 225 and 228 bp 
in length. However, quantification of these bands showed that HDR only occurred in 3.4% of 
the transfected cells, even though more than 50% of the amplified alleles experienced the 
micro-deletion. This indicated that a large proportion of the alleles that underwent this micro-
deletion were not repaired according to the ssODN by the HDR pathway. The repair of the F1 
224 target site produced digested products of 225 and 427 bp. The repair of the R2 228 target 
site generated products that were 228 and 423 bp long. The HDR of the individual sgRNA F1 
224 and R2 228-mediated DSBs occurred at a frequency of 5.9 and 9.3%, respectively 
(Figure 13D). HDR of the KRAS locus was undetected in the controls, which either excluded 
the ssODN repair template, or the CRISPR/Cas9 components for DSB induction. This 
indicated that the observed HDR of the DSBs was not mediated by an endogenous 
homologous sequence that happened to also harbour an EcoRI restriction site (shown by 
cleavage only), or that the integration of the EcoRI restriction site was not from spontaneous 
HR with the ssODNs (shown by donor only). From this, it could be seen that the CRISPR/
Cas9 system was able to stimulate HDR in the KRAS gene locus, through the introduction of 
single DSBs as well as a micro-deletion. Furthermore, this targeted DNA damage was able to 
be repaired according to small ssODN repair templates. 
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Figure 13: HDR of the individual DSBs and the micro-deletion with ssODNs. (A) A schematic showing the 
design of each 90-mer ssODN to repair the individual DSBs (top) and the micro-deletion (bottom) mediated by 
sgRNA F1 224 and R2 228. The homology arms of F1 ssODN and R2 ssODN flanked sequences directly 
adjacent to their respective DSBs. F1+R2 ssODN was designed to flank distal sequences that were outside of the 
F1 224 and R2 228 DSBs, for the repair of the micro-deletion. Each ssODN carried the EcoRI recognition site 
that was destined to be integrated into the KRAS gene via HDR. (B) PCR products of this repair region were 
amplified from gDNA. Controls for this experiment included cells that were transfected with the CRISPR/Cas9 
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components without the ssODN (cleavage only), or the ssODN without the CRISPR/Cas9 components (donor 
only). (C) A polyacrylamide gel showing the EcoRI digested PCR products. Successfully digested products were 
the result of the integration of the EcoRI recognition site into the KRAS gene, via HDR with the ssODNs. The 
density of the bands of digested products were quantified by densitometry to determine the efficiency of HDR. 
(D) The HDR efficiency was measured from triplicate experiments (mean±SD, *p<0.05, unpaired Student’s t-
test). 
3.5 Testing the “dual cut” strategy for the production of G>T KRAS mutants 
In order to generate selectable recombinant cells that harbour a desired point mutation, two 
genetic modifications have to be successfully introduced simultaneously into the gene region 
of interest. This commonly involves the insertion of a selection cassette into the nearest 
intronic sequence, where it can be integrated and expressed without affecting the gene coding 
sequence. The accompanying point mutation is often targeted to alter an exonic gene coding 
sequence. Traditional strategies employed to do this, involve introducing a targeted DSB to 
stimulate HDR according to a donor DNA construct that contains these two elements. This 
construct usually consists of two homology arms, which directly flank the DSB site. One of 
these homology arms will not completely be homologous to the target, with the point 
mutation variant embedded in its sequence. In between the two homology arms is the 
selection cassette. The repair of the DSB according to this donor sequence results in the 
integration of the expression cassette into the intronic sequence, and the point mutation into 
the targeted exon. However, due to the short gene conversion tracts in mammalian cells, the 
amount of DNA transferred from the donor construct to the gene locus diminishes greatly as 
the distance between the DSB site and the genetic modification increases (Elliott et al., 1998). 
Therefore, with the use of a single DSB, the successful co-transfer of both the expression 
cassette and the point mutation is often very inefficient when the two points of gene 
modification, that is, the insertion sites within the intron and exon, are far apart. This often 
results in the production of recombinant cells that are positive for the selection cassette and 
negative for the point mutation (Figure 14). This effect is further exacerbated when 
considerations into the preservation of intronic splicing elements are taken into account. In 
order to prevent the insertion of the expression cassette from interfering with gene splicing, 
the DSB site needs to be moved sufficiently far away from the intron-exon junction. Work 
done by Elliot et al. have demonstrated that gene conversion drops by a massive 60% when 
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the intended modification is a mere 46 bp away from the DSB site. From this, it was 
predicted that the success of producing selectable KRAS (G>T) mutants would be very 
limited with the single cut strategy, as the distance between the safe intronic insertion site and 
the exonic mutation point is 94 bp apart.  
In order to overcome this limitation, a “dual-cut” cleavage and repair strategy, using the 
CRISPR/Cas9 system, was tested. This involved introducing two simultaneous DSBs that 
flanked the intron-exon junction of interest, resulting in the deletion of the entire region 
between the DSBs. This region was then reconstituted according to a specially designed 
dsDNA donor, which functionally separated the intended gene modification elements (the 
selection cassette and the point mutation) from the homology arms. In this way, the homology 
arms, which are homologous to the outside of each DSB, function solely to direct the 
construct to the target region. The insertion DNA in between these two homology arms, 
serves to replace the deleted gene fragment with a modified gene sequence that contains the 
mutation, and introduces the selection cassette into the affected intron. This strategy should 
overcome the limitations of the single cut strategy, as the introduction of the two gene 
modifications are independent of gene conversion tract lengths. Also, by removing the point 
mutation from the homology arms, complete homology with the target sequence was 
maintained. This should further improve the efficiency of gene conversion, as small levels of 
homology divergence have been shown to greatly decrease the levels of recombination 
(Elliott et al., 1998). Furthermore, this strategy will allow for the introduction of multiple 
point mutations within the gene sequence, without affecting the rate of recombination. This 
strategy was tested by introducing two simultaneous DSBs into the exon 2 region of the 
KRAS gene, using sgRNA F1 224 and R2 228. The resultant micro-deletion, which was 
previously demonstrated, was repaired according to a donor DNA template which was 
designed to aid the successful co-insertion of both the oncogenic G>T transversion in exon 2 
and the accompanying selection cassette into intron 1 (Figure 14). 
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 Figure 14: The envisioned “dual cut” strategy versus the tradition “single cut” strategy to modify the 
KRAS gene. The extent of gene conversion is limited with the traditional single cut strategy, which uses a donor 
design that has two homology arms (HAs) that directly flank the DSB site. The successful co-transfer of both 
the gene mutation and the selection marker cassette (SM) into sites that are 94 bp apart will be very inefficient 
as a result of short gene conversion tracts. The “dual cut” strategy should overcome this, by deleting the entire 
region between the two sites, and then reconstituting this with a modified gene sequence that contains the 
mutation and the selection marker. 
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3.5.1 dsDNA donor assembly 
The dsDNA donor construct was designed to reconstitute the deleted KRAS gene sequence 
with the activating G>T mutation as well as insert a selection cassette that would allow for 
the isolation of recombinant cell clones. The dsDNA donor was composed of a 5ʹ and 3ʹ 
homology arm, which were designed to flank the sequences outside of each 5ʹ and 3ʹ DSB, 
respectively. In between the two homology arms is the insertion DNA sequence that is 
comprised of the selection cassette and the KRS. The expression cassette is driven by a 
constitutively active SV40 promoter, which expresses the genes for eGFP and NeoR (G418 
resistance), allowing for a fluorescence and antibiotic-based approach for the selection of 
recombinant cells. Translation of the two selection markers occurs off a single transcript, 
after which the chimeric protein molecule is separated through the self-cleaving properties of 
the embedded 2A peptide linker. It is worth noting that the expression of this selection 
cassette occurs in the opposite orientation to that of the KRAS gene, preventing transcriptional 
read-through. In this way, the inserted DNA cassette is as isolated as possible from the 
endogenous KRAS gene function. Immediately downstream of this expression cassette is the 
KRS. This feature is inserted along with the selection cassette and is designed to replace the 
deleted KRAS DNA with a modified gene sequence that contains the oncogenic G>T 
transversion. With this repair template design, the desired gene modifications are completely 
independent of the homology arms, but are rather all located in between the two homology 
arms. This dedicates the homology arms for gene targeting purposes only, while the DNA in 
between these two arms is knocked-in to introduce the genetic modifications. This design 
should eliminate the loss of donor DNA features that result from short mammalian gene 
conversion tracts.  
This dsDNA donor was created by fusing individual genetic parts together using overlap-
extension PCRs. This assembly method allowed for the multiple DNA parts to be seamlessly 
assembled together in two consecutive PCRs, which would have otherwise required several 
steps if traditional cloning methods were used. Each genetic part was amplified using PCR 
and was visualised on an agarose gel and compared to a DNA ladder to ensure that the correct 
product was being amplified. All the DNA parts for the dsDNA donor were successfully 
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amplified. The eGFP (875 bp), KRS (191 bp) and the SV40-NeoR (1 332 bp) fragments were 
fused together via terminal overlapping linker sequences to generate the insertion DNA 
cassette (2 349 bp). Because fine resolution of larger DNA fragments is lost on agarose gels, 
direct comparison of this product to the DNA ladder to ensure complete assembly was not 
accurate. Therefore, a truncated product which lacked the addition of the small KRS fragment 
was generated as a comparative control. A small size shift can be clearly seen between the 
truncated insertion DNA cassette and the full insertion DNA cassette, indicating that the small 
KRS fragment was successfully assembled along with the eGFP and NeoR fragments (Figure 
15A). A 5ʹ homology arm (437 bp) and a 3ʹ homology arm (432 bp) were then added to the 
terminals of the insertion DNA cassette in another overlap-extension PCR. An upward shift of 
762 bps can be clearly seen between the insertion DNA cassette and the completed dsDNA 
donor (3 111 bp), indicating successfully fusion of the homology arms (Figure 15B). 
Following the successful assembly of the dsDNA donor, Sanger sequencing confirmed the 
sequence integrity of the construct, particularly, the inclusion of the G>T mutation in the 
KRS (Figure 15C). Furthermore, florescent images of HEK 293 cells, 48 hours after being 
transfected with the dsDNA donor, showed that eGFP was successfully produced from the 
construct, albeit at a lower efficiency than pCI-NeoR-eGFP (Figure 15D). From the images, 
approximately 30% of the cells transfected with the dsDNA donor are fluorescing green. This 
is substantially lower than the 70% of fluorescent cells seen in the pCI-NeoR-eGFP 
transfection. Nevertheless, the production of eGFP is indicative of the co-expression of the 
upstream NeoR gene, based on the design of the construct. This shows that the expression 
cassette of the dsDNA donor is functional for fluorescence or antibiotic-based selection 
strategies.  
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 Figure 15: Assembly and verification of dsDNA donor construct. (A) An agarose gel showing each of the 
dsDNA donor fragments, which were generated with PCR. These products were fused together in an overlap 
extension PCR to produce the insertion DNA cassette, which comprised of the expression cassette and the KRAS 
reconstitution sequence (KRS). A truncated product was generated to serve as a size control to ensure the 
successful fusion of all the components. (B) The 5ʹ and 3ʹ HAs were amplified from gDNA and added to the 
terminals of the insertion DNA cassette through another overlap extension PCR. (C) Sanger sequencing was 
used to confirm the sequence integrity of the dsDNA donor. The chromatograms show a portion of this sequence 
that verifies the presence of the G>T mutation in the dsDNA donor construct. This was compared WT allele 
from the gDNA of HEK 293 cells. (D) Fluorescence images of HEK 293 cells 48 hours after being transfected 
with the dsDNA donor construct to test the functionality of the expression cassette. Cells transfected with pCI-
NeoR-eGFP or water (mock) served as a positive and negative control, respectively. 
3.5.2 HDR efficiency with the dsDNA donor using the “dual cut” strategy 
To test the performance of the “dual cut” strategy, the amount of KRAS mutant DNA, as a 
result of successful donor integration, was measured. The detection and quantification of 
genome engineering outcomes is quite challenging, with conventional methods relying on the 
enrichment and isolation of potential recombinant cells and then screening clonal populations 
for the targeted genomic modification. This process is labour intensive and only provides 
empirical data collected from a sub-population of cells selected for screening. Furthermore, 
such enrichment techniques often result in the selection of illegitimate recombinants that have 
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arisen as a result of random donor integration. The advent of high-throughput sequencing 
technologies provide a more robust method for assessing gene modification outcomes across 
an entire cell population (Hendel et al., 2014). However, these methods are limited by their 
high cost and the need for intensive data analysis. In this study, a qPCR strategy was devised 
to quantify the efficiency of CRISPR/Cas9-mediated HDR with the dsDNA donor. This was 
performed on gDNA, which was extracted from the entire cell population grown in antibiotic-
free conditions. This provided a simple way to detect and quantify the integration of the 
dsDNA donor across the entire cell population, without the need for clonal isolation of 
recombinants or reporter systems. Furthermore, with the lack of any selection pressure, the 
enrichment of illegitimate recombinants, and hence false positives, was also minimised. The 
detected amount of mutant KRAS DNA, relative to the total amount of KRAS DNA detected, 
gave an indication of how efficient the CRISPR/Cas9-mediated, “dual cut” knock-in process 
was. The use of qPCR allowed for the very specific and sensitive detection and quantification 
of the genomic integration of the complete dsDNA donor cassette (detected through the use 
of primer sets A-D) (Figure 16A) in the cell population 3 and 14 days post-transfection. This 
allowed for stable genomic integrants to be detected and monitored over time, as the residual 
episomal DNA from the transient transfection was diluted with cell proliferation. 
Primer set A spanned the gene-donor junction, allowing for the detection of integrated donor 
DNA in the KRAS gene. From this, the insertion of the linearised dsDNA donor cassette was 
the most successful when sgRNA F1 224 and sgRNA R2 228 were employed together. This 
demonstrates that the “dual cut” strategy, which is designed to mitigate gene conversion 
limitations, is functional. However, interestingly, single DSBs were also able to mediate the 
insertion of this dsDNA donor, indicating that the asymmetric binding of one homology arm 
proximal to the respective DSB was sufficient for HDR. Transfections that were sgRNA 
deficient showed no detectable dsDNA donor integration. This confirms that the detected 
integration of the donor into the target sequence did not occur spontaneously. Transfections 
with sgRNA F1 224, sgRNA R2 228, pX330 and a mock donor PCR product also failed to 
show any amplification, indicating that the dsDNA donor was responsible for the detected 
HDR. Primer set B measured the amount of episomal DNA in the transiently transfected 
cells, over time. After 3 days, the levels of episomal DNA detected were similar across all the 
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samples, with the only exception being the transfection for the dual cleavage, which involved 
using twice as much sgRNA expression plasmid. This indicates that the amount of DNA 
entering the cells in each sample was the same, reflecting a constant transfection efficiency. 
The dilution of the episomal DNA from transient transfection (the linear dsDNA donor, 
pX330 and pcDNA.sgRNA-KRAS) was apparent after 14 days (for 11 passages), with a 
dramatic drop in the levels of detected episomal DNA by approximately 99% in each sample. 
Despite this, readily detectable amounts of episomal DNA were still present in the transfected 
cells after 14 days of sub-culture (600-1000-fold relative to β-actin). Primer set C, an allele 
specific primer, was designed to detect mutated KRAS alleles with the G>T transversion. 
Comparison of this to the quantified DNA of primer set A should have provided an idea of 
how successful the co-transfer of the expression cassette and the mutation was. Initially, the 
detected amount of DNA with primer set C was largely reflective of the dsDNA donor 
construct that existed episomally in the cells. It was expected that as the episomal DNA was 
diluted out of the transfected cells, the amount of modified (G>T) KRAS DNA, as a result of 
dsDNA donor integration into the KRAS gene, would become apparent. However, based on 
the observations made with primer set B, significant amounts of episomal dsDNA donor were 
still present in the cells after 14 days of sub-culture (approximately 150-fold of β-actin). The 
detection of the introduction of the G>T point mutation into the KRAS gene was 
overwhelmed by this background noise. The use of a mock donor for transfection yielded no 
detectable amplification with this primer set, which shows that the allele specific primer set is 
specific to the mutation which does not naturally exist in HEK 293 cells. Primer set D 
reflected the total amount of KRAS DNA in each sample, and remained relatively constant 
across all samples, throughout the 14 day period (Figure 16B). 
The amount of detected dsDNA donor integrated into the KRAS gene (data from primer set 
A), taken as a percentage of the total KRAS DNA detected (data from primer set D), was used 
as a metric for site-specific donor integration efficiency (Figure 16D). The micro-deletion 
facilitated the integration of this large donor DNA sequence in 0.028 and 0.123% of the 
transfected cells, after 3 and 14 days, respectively. This is better by a factor of 1.6 and 1.8-
fold, respective to the 3 and 14 days post-transfection, when compared to that of the single 
DSB generated by sgRNA F1 224. Similarly, it was found to be more efficient by 1.6 and 2.9-
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fold compared to sgRNA R2 228, after 3 and 14 days, respectively. This showed that the 
application of both the sgRNAs to induce a micro-deletion facilitates the HDR process with 
this donor design. It is also worth noting that the detected amount of HDR for the three 
cleavage scenarios substantially increased, by a factor of 2.6 - 4.6-fold, after 14 days. 
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Figure 16: Integration efficiency of the dsDNA donor. (A) A schematic outlining the primer-target 
interactions for the qPCR strategy used to determine the integration efficiency of the dsDNA donor into the 
KRAS gene. Quantification was done on extracted gDNA 3 and 14 days post-transfection. (B) Relative amounts 
of detected target DNA of each primer set, normalised to β-actin. The error bars represent the SD calculated 
from the results of a triplicate experiment. Transfections with an empty sgRNA expression plasmid or a mock 
donor served as negative control. (C) The percentage of KRAS alleles that had successfully undergone dsDNA 
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donor integration at the KRAS gene locus, as calculated by taking the data from primer set A (integration events) 
as a percentage of primer set D (total KRAS DNA) (mean±SD, *denotes no detected amplification). 
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4. Discussion 
The results demonstrate that the CRISPR/Cas9 system can modify the human KRAS gene in 
cultured HEK 293 cells in various, highly specific ways, which are each useful for genome 
engineering. The use of different sgRNA guide sequences, directed to the same region of the 
KRAS gene showed varying activity, possibly implicating a role of guide sequence 
composition on sgRNA functionality. Also, various strategies for the HDR of DSBs were 
simulated for the precise modification of the KRAS gene. From this, useful insights into 
sgRNA design and CRISPR/Cas9-mediated gene modification were gained, allowing for 
various considerations and strategies for the efficient and robust use of this system for 
genome engineering to be highlighted. 
4.1 sgRNA guide sequence composition affects CRISPR/Cas9 indel forming activity 
The Surveyor Assay showed that all the sgRNAs were functional and could successfully 
mediate the introduction of a DSB in the intron 1 - exon 2 region of the KRAS gene locus. 
The frequency of indel formation was variable, ranging from 1.3 - 6.0%. It has been 
demonstrated that the CRISPR/Cas9 system is able to introduce indels at an efficiency of 
greater than 50% (Hsu et al., 2013, Ran et al., 2013b, Fu et al., 2014). However, in these 
reports, different genes, which may be associated with variations in chromatin structure or 
repair pathway priority, were targeted. These factors are most likely to affect obtainable 
cleavage efficiencies. A pair of TALENs designed to cleave in exon 2 of the KRAS gene was 
shown to achieve an indel formation frequency of 9.4% (Reyon et al., 2012). In comparison 
to the efficiency observed with the CRISPR/Cas9 system here, the TALEN pair was 1.6 - 7.2-
fold more efficient at indel formation than the tested sgRNAs. It is interesting that the 
CRISPR/Cas9 system performed poorly compared to the TALEN pair, and that the activity of 
each sgRNA was so variable, even though they all target sequences of very close proximity 
(less than 250 bp apart) within the KRAS gene. Because of this, these variations are not likely 
to be the result of differences in the genomic architecture of the sequences that the CRISPR/
Cas9 system has to access, but rather due to factors that are intrinsic to the technology itself, 
which may limit its activity. It is possible that guide sequence composition may affect the 
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activity of the CRISPR/Cas9 system, and that these sequence variations may be tolerated 
differently to impact function. 
It has been shown that the secondary structure of the RNA scaffold of the sgRNA is 
imperative for its interaction with the Cas9 protein. The repeat:anti-repeat duplex and stem 
loop 1 have been shown to be crucial for Cas9 function. Stem loop 2 and 3 have been found 
to play a supportive role, through stabilising the sgRNA and facilitating sgRNA-Cas9 
complex formation (Chen et al., 2013, Hsu et al., 2013, Jinek et al., 2014, Nishimasu et al., 
2014). The guide sequence introduced upstream of the RNA scaffold may potentially alter 
base-pair interactions that maintain the integrity of these functional secondary structures, 
resulting in the formation of dysfunctional sgRNA molecules that cannot efficiently assemble 
with the Cas9 endonuclease and activate it. In order to observe base-pair interactions between 
the guide sequence and the RNA scaffold, the online RNA folding simulation tool, 
RNAstructure (Reuter and Mathews, 2010), was used to predict the secondary structure of 
sgRNA F1 224, F3 226, R1 227 and R2 228 (Figure 17A). These were compared to the 
predicted secondary structure of the RNA scaffold in the absence of a guide sequence. The 
MaxExpect algorithm was used to generate structures that were based on the most probable 
base-pair interactions rather than the lowest free energy, which can be unrealistic under 
physiological conditions. sgRNA F2 225 was excluded from these analyses because it was 
designed to make use of the degenerate NAG PAM site, which has been shown to be far less 
efficient than when the canonical NGG PAM site is used (Hsu et al., 2013). In all of the 
predicted structures, the repeat:anti-repeat duplex is preserved exactly as seen in the native 
RNA scaffold. The structures predicted for sgRNA F3 226, R1 227 and R2 228 further show 
that stem loop 2 and 3 are also maintained. However, the critical stem loop 1 is disrupted in 
all of the sgRNA structures through direct base-pair interactions with the guide sequence, or 
resultant allosteric effects. This may have adversely affected the potential performance of the 
CRISPR/Cas9 system, resulting in its lower targeting activity of the KRAS gene locus 
compared to the TALEN pair. Interestingly, sgRNA F1 224, which was the most efficient, 
seems to lack the most structural features of the RNA scaffold. The predicted structure of this 
sgRNA displays an unwanted stem loop after the repeat:anti-repeat duplex and only maintains 
stem loop 3.  
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 Figure 17: Analysis of guide sequence composition on sgRNA function. (A) Predicted RNA structures of four 
of the sgRNAs designed to target the KRAS gene. The native structure of the RNA scaffold without a guide 
sequence was used for comparison. The structures were predicted based on the most probable base-pair 
interactions. (B) Correlation between the stability of the sgRNA structures (as measured by Gibbs free energy) 
and the indel formation efficiency of the sgRNAs (p = 0.0062, F-test). (C) Correlation between the number of 
potential off-targets of each sgRNA and its indel forming activity (p = 0.18, F-test). (D) Correlation between the 
melting temperature of the guide sequence (calculated using the nearest-neighbour method) and sgRNA indel 
forming activity (p = 0.0072, F-test).  
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By inspecting these predicted secondary structures, it can be seen that the 20 nt guide 
sequence does interact with the RNA scaffold and disrupts various structural elements. But 
the maintenance of these stem loops, particularly stem loop 1, does not seem to account for 
the observed variations in sgRNA activity. It is worth noting, however, that the structure of 
sgRNA F1 224 looks significantly more “open”, compared to the other three sgRNA 
structures, which adopt an almost completely double-stranded duplex formation. The stability 
of these structures is dependent on the strength and extent of base-pair interactions of the 
RNA scaffold and the guide sequence. Analysis of the thermodynamic properties of each of 
these structures, using mFold (Zuker, 2003), showed a very significant (p = 0.0062) negative 
correlation (r2 = 0.54) between the sgRNA structure stability, as measured by Gibbs free 
energy (∆G), and indel formation frequency (Figure 17B). Therefore, sgRNA F1 224, which 
has the least thermodynamically stable structure, displayed the most efficient activity. This 
can be explained by the ability of less stable sgRNA structures being more accessible to, and 
reactive with, the Cas9 endonuclease. Initial sgRNA-Cas9 interactions may be more 
energetically favourable with such structures and serve to catalyse a conformational change 
of the sgRNA to yield a structurally functional sgRNA. Such interactions may be less 
thermodynamically favourable with sgRNAs that are inherently stable as a result of strong 
intra-molecular base-pair interactions, inhibiting their efficient transformation into the 
functional conformation upon Cas9 interaction. Therefore, the process of sgRNA 
conformational change and its interaction with the Cas9 protein to produce an active 
complex, may be a cooperative process that is limited by the stability of the unbound sgRNA 
molecule. 
The involvement of the guide sequence in sgRNA functionality prompted the investigation of 
other factors concerning the guide sequence that may also contribute to the observed sgRNA 
activity. It was hypothesised that the number of potential off-target sites of each sgRNA may 
affect the efficiency of the CRISPR/Cas9 system. Potential off-target substrates may possibly 
compete for the CRISPR/Cas9 components, resulting in the decrease of the frequency of 
KRAS targeted DSBs. Comparing the observed indel percentage with the number of potential 
off-target sites (determined with the CRISPR Design Tool), showed an insignificant (p = 
0.18) and poor correlation (r2 = 0.17) (Figure 17C). This indicates that guide sequence off-
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targets do not significantly influence targeted sgRNA activity. The CRISPR/Cas9 components 
are probably sufficiently expressed to saturate all potential binding sites within the cell, 
eliminating any competitive effects. Interestingly, a very significant (p = 0.0072) negative 
correlation (r2 = 0.53) was observed between the indel formation efficiency and the melting 
temperature of the sgRNA guide sequence (Figure 17D). This correlation shows that the 
increase in the binding affinity of the guide sequence with the genomic target DNA leads to a 
decrease in sgRNA activity. This can possibly be explained by the inefficient recycling of the 
CRISPR/Cas9 complex. A strong guide sequence target-binding affinity may result in the 
sgRNA-Cas9 complex sequestering the target DNA after DSB induction, affecting the 
accessibility of the target site for NHEJ repair. However, this is inconsistent with the trend 
previously observed (Yang et al., 2013), who found the opposite, but relatively poor, (r2 = 
0.28) positive correlation between sgRNA function and melting temperature. Nevertheless, 
this shows that the binding affinity of the sgRNA guide sequence to its cognate target plays a 
role in the efficiency of DSB repair. It would be useful to test a series of sgRNAs with a large 
range of nucleotide binding affinities to determine the optimal melting temperature for 
sgRNA function. 
From this analysis, the guide sequence composition seems to be able to profoundly alter 
sgRNA function. Up to 54 and 53% of the variation observed in the efficiency of the 
CRISPR/Cas9 system to introduce indels in the KRAS gene, can be explained by sgRNA 
secondary structure stability and target sequence affinity, respectively. Both of these factors 
are affected by guide sequence composition. Therefore, guide sequence composition is an 
important factor that affects the robustness of CRISPR/Cas9 function and must be considered 
for the rational design of sgRNAs. However, because sgRNAs are so easy and cheap to 
generate, several guide sequences for a target region can be easily produced and tested in 
parallel to screen for the most efficient sgRNA. 
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4.2 CRISPR/Cas9-induced DSBs and micro-deletions can be predominantly repaired by 
different DNA repair pathways  
The CRISPR/Cas9 system has been shown be able to successfully stimulate the NHEJ repair 
pathway to yield site-specific gene mutations and micro-deletions. The versatility of this 
system was further demonstrated through its ability to facilitate precise gene modifications, 
via the HDR pathway. Individual DSBs as well as a micro-deletion in the KRAS gene locus 
were able to be precisely repaired according to a short 90-mer ssODN repair template. RFLP 
analysis and densitometry showed that HDR of individual CRISPR/Cas9-mediated DSBs 
(sgRNA F1 224 and R2 228) occurred at an efficiency comparable to the ~8% reported by 
Zhang et al. (Ran et al., 2013a). Comparing the frequency of HDR and NHEJ showed that 
each of the two sgRNAs gave rise to quite different gene modification outcomes. DSBs 
mediated by sgRNA F1 224 were able to stimulate NHEJ (6.01%) and HDR (5.87%) at 
similar rates. This suggests that this target site is not preferentially repaired by either 
pathway. Interestingly, the repair of the DSBs mediated by sgRNA R2 228 were 
preferentially repaired by HDR, which occurred at an efficiency of 9.27%. This is 
significantly higher than the 2.74% detected for NHEJ repair of this target site. It is known 
that certain genetic elements are highly conserved, and preferentially repaired by either the 
NHEJ or HDR pathway (Wang et al., 2004). sgRNA R2 228 targets the coding sequence in 
exon 2 of the KRAS gene, which is an oncogene that needs to be carefully preserved. It is 
possible that the integrity of this coding sequence is maintained through the suppression of 
NHEJ DNA repair at the exons of this gene, and are preferentially repaired through the HDR 
pathway. Therefore, in the Surveyor Assay, DSBs mediated by sgRNA R2 228 may have been 
predominantly repaired by HDR through the recruitment of the endogenous homologous 
sister chromatid (Santiago et al., 2008), and less frequently by the mutagenic NHEJ pathway. 
In this way, the activity of sgRNA R2 228 was not able to be detected with the Surveyor 
Assay at this site. This explains the low percentage of indel formation observed. Furthermore, 
the recruitment of the homologous allele, after a targeted DSB, places the sister allele within 
close proximity to the CRISPR/Cas9 complex, increasing the chances of a second DSB. This 
facilitates the cleaving efficiency of sgRNA R2 228. Together, the increased frequency of 
DSB generation and the repair pathway preference of this site, enhanced the HDR of sgRNA 
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R2 228 DSBs with the exogenous ssODN when it was introduced. This hypothesis explains 
the high rate of HDR with the ssODN observed, relative to the indel formation efficiency 
detected with the Surveyor Assay for sgRNA R2 228. This phenomenon was not seen with 
sgRNA F1 224, which targets a less vital upstream intronic sequence. However, to confirm 
this, more robust and sensitive methods, such as high-throughput sequencing, are required to 
accurately quantify the gene modification outcomes at the different sites. Such sensitive 
characterisation would allow for repair pathway preferences associated with different genetic 
elements to be more accurately determined. 
The simultaneous application of sgRNA F1 224 and sgRNA R2 228 was able to successful 
introduce a micro-deletion in the KRAS gene. It is expected that the observed micro-deletion 
only occurs with two concurrent DSBs, resulting in the excision of the DNA in between the 
two target sites. The agarose gels show that this deletion event was rare, with only a small 
fraction of transfected cells harbouring the deletion allele. This is possibly limited by the 
stochastic infrequency of the two sgRNAs binding to their cognate target sites, on the same 
copy of the KRAS gene, at the same time, and inducing DSBs simultaneously. However, the 
introduction of the F1+R2 ssODN, which was designed with homology arms that flank the 
outside of the micro-deletion, seemed to stimulate the frequency of this micro-deletion event 
quite profoundly. This is evident on the agarose gel from Figure 13B, which shows that the 
micro-deletion occurred 1 200-fold more frequently when the two sgRNAs were applied with 
the F1+R2 ssODN, than when only the two sgRNAs were applied without the repair 
template. Chen et al. showed in a study that specific gene deletions could be achieved 
efficiently by using ssODNs that were designed to have homology with distal chromosomal 
sequences to repair a single DSB (Chen et al., 2011). Therefore, it can be expected that single 
cuts introduced by the individual activity of sgRNA F1 224 and sgRNA R2 228 were 
sufficient to stimulate F1+R2 ssODN-mediated gene deletion. Furthermore, the occurrence of 
single cuts is stoichiometrically more favourable and likely to occur much more frequently 
than two simultaneous cuts, explaining why the gene deletion event occurred in only 4.1% of 
the transfected cells when the two sgRNAs were used in the absence of the F1+R2 ssODN, 
compared to the 53.2%, which was observed when the F1+R2 ssODN was included. 
Interestingly, however, RFLP analysis showed that only 3.4% of these deletion events were 
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repaired according to the F1+R2 ssODN, resulting in the successful integration of the EcoRI 
restriction site. This indicates that the remaining 50.1% of the observed micro-deletion events 
underwent NHEJ repair. It is uncertain as to how the F1+R2 ssODN so efficiently facilitates 
the introduction of this micro-deletion through the NHEJ pathway, without interacting with 
the homologous sequences around the DSB sites and recombining to introduce the EcoRI 
restriction site. Therefore, the predominant repair of the micro-deletion by the NHEJ pathway 
explains the poor HDR efficiency detected. 
From this, it seems that single DSBs and micro-deletions in the KRAS gene can be 
predominantly repaired by either HDR or NHEJ. The factors that govern this repair pathway 
preference is currently unclear, and may be related to cellular mechanisms that prioritise 
repair pathways for specific genetic elements. 
4.3 A “dual cut” CRISPR/Cas9 strategy can mediate the production of selectable G>T 
mutant KRAS cells 
A dsDNA donor cassette was created to introduce an oncogenic G>T mutation in the KRAS 
gene along with a selection cassette that would allow for the fluorescence or antibiotic-based 
selection of mutant clones. This construct was designed to repair the micro-deletion 
generated by the simultaneous activity of sgRNA F1 224 and R2 228, so that common gene 
conversion limitations, intrinsic to the short gene conversion tracts of mammalian cells, could 
be overcome. This involved functionally separating the dsDNA donor cassette into two 
components: the homology arms and the insertion DNA. The homology arms were designed 
to perform the sole function of directing the donor construct to the gene target. The insertion 
DNA was responsible for the gene modifications. This was designed to reconstitute the 
deleted KRAS gene fragment with a modified sequence that contained the point mutation of 
interest, as well as insert the selection cassette into the adjacent intron. With this strategy, the 
point mutation and the expression cassette should always be successfully co-inserted into the 
into the KRAS gene, whenever an integration event occurred. 
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The fluorescence images of the HEK 293 cells transfected with the dsDNA donor construct 
showed that the expression cassette was functional. The observed eGFP indicated that the 
upstream NeoR gene must have also been concurrently expressed and translated. However, it 
can be seen that eGFP expression occurs less efficiently compared to that of the pCI-NeoR-
eGFP plasmid. This is because the dsDNA donor makes use of a SV40 promoter, which has 
been shown to be approximately 2.5-fold less efficient, in HEK 293 cells, than the CMV 
promoter of pCI-NeoR-eGFP (Qin et al., 2010). Moreover, the eGFP transgene of pCI-NeoR-
eGFP is preceded by a short intronic sequence, which is designed to stabilise and improve its 
expression (Xia et al., 2006). The folding kinetics and translation efficiency of the eGFP 
protein are also probably adversely affected by the production of an eGFP-NeoR chimera, 
which needs to be cleaved apart by the 2A-self cleaving peptide, before yielding individual 
functional proteins. The use of a stronger promoter might off-set the slower kinetics 
associated with the post-translational processing required for this chimeric protein. However, 
with the current dsDNA donor design, allowing sufficient time for the expression of these 
selection markers to occur, before the application of selective pressure, should overcome 
these limitations. 
The data shows that the dual cleavage strategy was able to successfully facilitate the 
integration of the dsDNA donor into the targeted KRAS gene. HDR experiments with the 
ssODN and this dsDNA donor show that spontaneous HR (control transfections with the 
donor template only), without a DSB at the homologous target site, was undetectable. This 
suggests that random off-target integration events of the repair construct should be extremely 
rare as these sites lack the homology and the DSB to stimulate recombination. However, this 
needs to be confirmed by high-throughput sequencing to analyse the modified genome in 
more depth to get a better indication of HDR specificity.  
The dual cleavage gene-editing strategy was able to generate up to 60 bi-allelic or 123 mono-
allelic KRAS mutants out of one million cells. This is significantly higher than what can be 
achieved through gene targeting strategies that rely on spontaneous HR. Interestingly, the 
introduction of a single DSB by sgRNA F1 224 or sgRNA R2 228 was sufficient to facilitate 
the integration of the dsDNA donor sequence. However, this occurred at a significantly lower 
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efficiency than when both sgRNAs were employed simultaneously. This can be explained by 
the repair of the single cuts only being mediated by one of the homology arms of the dsDNA 
donor, whereas the micro-deletion makes use of both. It is also worth noting that the 
frequency of dsDNA donor integration improved over time, irrespective of the cleavage 
introduced. This is unlikely to be the result of slow CRISPR/Cas9-mediated HDR kinetics, as 
each cell is supplied with an abundance of CRISPR/Cas9 components and dsDNA donor to 
efficiently target the both KRAS alleles. Variations in cell numbers across the 14 day 
experiment period cannot explain this either, as these were kept relatively constant, as shown 
by the quantity of total KRAS DNA detected. Furthermore, this increase in the signal of 
integrated donor could also not be a result of spontaneous HR of the dsDNA donor with the 
KRAS gene over time. This is evident in the sgRNA-deficient control which showed no sign 
of spontaneous HR and targeted donor integration after 14 days. However, it is known that 
KRAS activity promotes cell growth and proliferation. The introduction of the activating 
point mutation into the KRAS gene results in the production of a constitutively active Kras 
protein mutant, which imbues the modified cells with a growth advantage (Loupakis et al., 
2009). Therefore, KRAS mutant cells could have possibly been proliferating at a greater rate 
than the WT cells, resulting in the enrichment of the mutant cell population and the 
subsequent elevation in the detected levels of integrated dsDNA donor over time. 
For the conclusive assessment of this dual cut strategy to successfully and efficiently 
facilitate the co-integration of both the point mutation and the expression cassette, the 
quantity of integrated expression cassette DNA (measured by primer set A) needs to be 
compared to that of the point mutation (measured by the allele specific primer set C). A ratio 
of 1 would indicate that there was a 100% efficiency in the co-transfer of these two genetic 
elements into the KRAS gene locus. However, this analysis could not be made, as vast 
amounts of residual episomal DNA from the transient transfection could still be detected in 
the cells, even after 14 days of sub-culture. Despite using the linearised form of the dsDNA 
donor for transfection, which was predicted to degrade much more efficiently episomally, 
compared to the plasmid format, approximately 20-30% of the episomal DNA detected was 
comprised of the dsDNA donor. This generated an overwhelming amount of signal noise that 
prevented the detection and quantification of successfully mutated KRAS sequences. In order 
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to successfully make these comparisons, less DNA should be used in the transfections so that 
it can be quickly diluted out after the modification. This may sacrifice the performance of this 
strategy, but qPCR should be sensitive enough to detect very rare events. Alternatively, the 
transfected cells could simply be cultured for a longer amount of time. Regardless of this, it 
has been demonstrated that the CRISPR/Cas9 system can mediate the introduction of a large 
DNA cassette into the KRAS gene locus. Furthermore, these recombinant cells can be isolated 
using fluorescent activated cell sorting or G418 selection and clonally expanded to generate 
cell lines for further study. 
5. Conclusion 
In this work, the use of the CRISPR/Cas9 system was explored to modify the human KRAS 
gene. The system was able to efficiently generate targeted DSBs and gene deletions, which 
were successfully repaired with small ssODNs or a custom designed dsDNA donor construct. 
The work highlights some important parameters that need to be considered when designing 
sgRNAs for the CRISPR/Cas9 system. The choice of guide sequence composition should aim 
to minimise base-pair interactions between the guide sequence and the RNA scaffold that 
stabilise the sgRNA structure. Furthermore, this sequence should not have a binding affinity 
to the target site that needs a temperature of greater than approximately 54ºC to be abolished. 
The repair of CRISPR/Cas9-mediated DSBs and micro-deletions can be easily and 
conveniently repaired using ssODNs for precise gene modifications. However, the gene target 
chosen may be preferentially repaired by NHEJ or HDR, affecting the efficiency of the 
desired outcome. The “dual cut” strategy was also functional to efficiently generate a high 
number of selectable mutant recombinant cells. The use of this strategy should overcome the 
gene conversion limitations in mammalian cells. Together, this work highlights some 
important considerations for the use of the CRISPR/Cas9 system for efficient and robust gene 
modification. 
The CRISPR/Cas9 system is a novel genome engineering tool that has proven to be able 
efficiently facilitate the manipulation of DNA. The multiplex potential and the ease at which 
the CRISPR/Cas9 system can be applied is ideal for constructing biological models that more 
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accurately recapitulate the genetic elements of complex diseases such as cancer. However, the 
off-target effects of this system is concerning and must be considered, particularly for gene 
therapy applications. The CRISPR/Cas9 system is still a very new technology and will 
undoubtedly have to undergo substantial development to overcome current limitations. As our 
understanding of the CRISPR/Cas9 system improves, re-engineering of the system through 
rational design to improve target specificity of the system may be possible. Furthermore, new 
CRISPR/Cas systems are continuously being defined, providing a collection of systems with 
unique characteristics which may better satisfy the needs of genome engineering. 
Nevertheless, the functionality of the current system from S. pyogenes, for gene editing, has 
proven to be quite efficient and versatile. The expansion of this system to a general gene 
localisation platform, allows for the genome to be interrogated in even more ways. The 
CRISPR/Cas9 system currently provides a powerful, highly engineerable and cost-effective 
platform to efficiently interrogate and creatively explore the genome.  
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7. Appendix 
7.1 Supplementary data 
Supplementary figure 1: Optimisation of ssODN dosage for maximum HDR. A 5-fold dilution, ranging 
from 0.4 to 10 µl, of a 100 µM stock of F1 ssODN was tested for optimal HDR of sgRNA F1 224-mediated 
DSBs. 250 000 HEK 293 cells were transfected with the different doses and the gDNA was extracted from these 
cells 72 hours afterwards. PCR products amplified from this gene region were digested with the EcoRI 
restriction enzyme to detect HDR events. (A) A polyacrylamide gel showing the digested PCR products when 
different doses of ssODN are applied. Densitometry was used to quantify the digested bands and calculate the 
HDR percentage (B) Quantification of the digested bands show that HDR is linearly dose-dependent on the 
amount of ssODN used in the transfection between 0.4 and 2 µl. Increasing the amount of transfected ssODN to 
10 µl led to a substantial decrease in HDR efficiency. From this 2 µl of ssODN (100 µM) was deemed to be 
optimal for HDR and was applied in subsequent experiments. The data here represents measurements made 
from a triplicate experiment (mean±SD).  
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Supplementary figure 2: Optimisation of the primer sets for qPCR. Amplification plots generated with the 
different primer sets at different annealing temperatures. This was done to determine the optimal annealing 
temperature for each primer set. Each reaction was carried out in duplicate and the optimal temperature was 
chosen on the basis of consistent amplification patterns from both reactions. The optimal annealing temperatures 
are as follows: Primer set A - 55ºC, primer set B - 55ºC, primer set C - 60ºC, primer set D - 60ºC , β-actin primer 
set - 55ºC. No template controls were set up for each reaction. No amplification was detected in these reactions 
for primer sets C, D and β-actin. However, primer set A and B showed some late amplification in these water 
controls, but these were regarded as primer dimers as they amplified more than five cycles later than the desired 
product.  
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 Supplementary figure 3: Melt curve analysis to validate specific primer amplification. (A) At the end of 
each PCR, the generated DNA duplex products were melted and the SYBR green signal was monitored as it 
diminished. The melt curves show that each primer set was very specific, only amplifying a single specific 
product. Signs of the primer dimers can be clearly seen in the curves of primer set B and the β-actin as the small 
peak that preceded the major peak. (B) The products generated with each primer set were also visualised on an 
agarose gel to ensure that products of the correct size were being amplified. 
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Supplementary figure 4: The effect of different dsDNA donor concentrations and formats on HDR-
mediated construct integration. For this experiment, 250 000 HEK 293 cells were transfected with different 
amounts of linear or plasmid dsDNA donor to repair the micro-deletion as a result of the simultaneous activity 
of sgRNA F1 224 and R2 228. The qPCR strategy described in Figure 16A was used to assess the effect of linear 
and plasmid dsDNA donor, introduced into the cells at different concentrations, on HDR and construct 
integration. Primer set A was used to measure the amount of integrated dsDNA donor and primer set B for the 
quantification of the total amount of KRAS DNA in each sample. The percentage integration, as calculated by 
taking the amount of integrated DNA as a percentage of total KRAS DNA, showed that HDR reaches a 
saturation point when 6 µg of the linear dsDNA donor was used for transfection. Transfections with the plasmid 
form of the dsDNA donor did not show any sign of HDR saturation, and seemed to follow a dose-dependent 
trend for the tested range. However, the percentage integration detected with equal amounts of linear and 
plasmid dsDNA donor showed that the linear format was always a slightly more efficient. This is probably as a 
result of a larger number of dsDNA molecules per microgram of DNA used, as the linear dsDNA construct is 
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significantly smaller that the plasmid form. This also explains the early saturation of HDR seen with the linear 
construct. Interestingly, the plasmid format is not significantly less efficient that the linear format, even though 
far fewer dsDNA donor molecules are introduced per microgram of transfected DNA. This could possibly be 
explained by the stability of circular DNA, allowing them to persist and function for a longer period of time 
compared to the linear dsDNA donor, which is probably degraded much more quickly. However, with this in 
mind, linear dsDNA constructs are more advantageous for gene editing experiments. A large number of 
molecules can be efficiently introduced in the cells using a relatively smaller amount of DNA for transfection. 
Furthermore, their activity as a donor construct is very transient, as they are degraded relatively quickly, which 
is desirable in applications in which their presence may interfere with the experiment. 
7.2 Supplementary sequences 
7.2.1 dsDNA donor components 
Overlapping sequences are colour coded. 
> 5ʹ HA 
TAGCTGTTGCATATTGACTTCTAACACTTAGAGGTGGGGGTCCACTAGGAAAACTGTAACAATAAGA
GTGGAGATAGCTGTCAGCAACTTTTGTGAGGGTGTGCTACAGGGTGTAGAGCACTGTGAAGTCTCT
ACATGAGTGAAGTCATGATATGATCCTTTGAGAGCCTTTAGCCGCCGCAGAACAGCAGTCTGGCTAT
TTAGATAGAACAACTTGATTTTAAGATAAAAGAACTGTCTATGTAGCATTTATGCATTTTTCTTAAGCG
TCGATGGAGGAGTTTGTAAATGAAGTACAGTTCATTACGATACACGTCTGCAGTCAACTGGAATTTT
CATGATTGAATTTTGTAAGGTATTTTGAAATAATTTTTCATATAAAGGTGAGTTTGTATTAAAAGGTAC
TGGTGGAGTATTTGATAGTGTATTAACCTTAT 
> eGFP fragment 
G T T T G T A T T A A A A G G T A C T G G T G G A G T A T T T G A T A G T G T A T T A A C C T T A T 
CACACAAAAAACCAACACACAGATGTAATGAAAATAAAGATATTTTATTTCTAGAGTATACGGACCG
TTACTTGTACAGCTCGTCCATGCCGAGAGTGATCCCGGCGGCGGTCACGAACTCCAGCAGGACCAT
GTGATCGCGCTTCTCGTTGGGGTCTTTGCTCAGGGCGGACTGGGTGCTCAGGTAGTGGTTGTCGGG
CAGCAGCACGGGGCCGTCGCCGATGGGGGTGTTCTGCTGGTAGTGGTCGGCGAGCTGCACGCTGCC
GTCCTCGATGTTGTGGCGGATCTTGAAGTTCACCTTGATGCCGTTCTTCTGCTTGTCGGCCATGATAT
AGACGTTGTGGCTGTTGTAGTTGTACTCCAGCTTGTGCCCCAGGATGTTGCCGTCCTCCTTGAAGTC
GATGCCCTTCAGCTCGATGCGGTTCACCAGGGTGTCGCCCTCGAACTTCACCTCGGCGCGGGTCTTG
TAGTTGCCGTCGTCCTTGAAGAAGATGGTGCGCTCCTGGACGTAGCCTTCGGGCATGGCGGACTTG
AAGAAGTCGTGCTGCTTCATGTGGTCGGGGTAGCGGCTGAAGCACTGCACGCCGTAGGTCAGGGTG
GTCACGAGGGTGGGCCAGGGCACGGGCAGCTTGCCGGTGGTGCAGATGAACTTCAGGGTCAGCTT
GCCGTAGGTGGCATCGCCCTCGCCCTCGCCGGACACGCTGAACTTGTGGCCGTTTACGTCGCCGTCC
AGCTCGACCAGGATGGGCACCACCCCGGTGAACAGCTCCTCGCCCTTGCTCACCATGGGCCCAGGG
TTGGACTCGACGTCTCCCGCCAACTTGA 
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> SV40-NeoR fragment 
ACGTCTCCCGCCAACTTGAGAAGGTCAAAATTCAAAGTCTGTTTCACGAAGAACTCGTCAAGAAGG
CGATAGAAGGCGATGCGCTGCGAATCGGGAGCGGCGATACCGTAAAGCACGAGGAAGCGGTCAGC
CCATTCGCCGCCAAGCTCTTCAGCAATATCACGGGTAGCCAACGCTATGTCCTGATAGCGGTCCGCC
ACACCCAGCCGGCCACAGTCGATGAATCCAGAAAAGCGGCCATTTTCCACCATGATATTCGGCAAG
CAGGCATCGCCATGGGTCACGACGAGATCCTCGCCGTCGGGCATGCGCGCCTTGAGCCTGGCGAAC
AGTTCGGCTGGCGCGAGCCCCTGATGCTCTTCGTCCAGATCATCCTGATCGACAAGACCGGCTTCCA
TCCGAGTACGTGCTCGCTCGATGCGATGTTTCGCTTGGTGGTCGAATGGGCAGGTAGCCGGATCAAG
CGTATGCAGCCGCCGCATTGCATCAGCCATGATGGATACTTTCTCGGCAGGAGCAAGGTGAGATGAC
AGGAGATCCTGCCCCGGCACTTCGCCCAATAGCAGCCAGTCCCTTCCCGCTTCAGTGACAACGTCG
AGCACAGCTGCGCAAGGAACGCCCGTCGTGGCCAGCCACGATAGCCGCGCTGCCTCGTCCTGCAGT
TCATTCAGGGCACCGGACAGGTCGGTCTTGACAAAAAGAACCGGGCGCCCCTGCGCTGACAGCCG
GAACACGGCGGCATCAGAGCAGCCGATTGTCTGTTGTGCCCAGTCATAGCCGAATAGCCTCTCCACC
CAAGCGGCCGGAGAACCTGCGTGCAATCCATCTTGTTCAATCATGGTGGCTCTAGCCTTAAGTTCGA
GACTGTTGTGTCAGAAGAATCAAGCTTTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTA
CTTCTGGAATAGCTCAGAGGCCGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCA
TGGGGCGGAGAATGGGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGA
CTATGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTT
CCACACCTGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGG
ACTTTCCACACCCTAACTGACACACATTCCACAGCTGGTTCTTTCCGCCTCAGAAGGTACCTAACCA
AGTTCCTCTTTCAGAGGTTATTTCAGGCCATGGTGCTGCGCGTGTGACATGTTCTAATATAGTCACAT
TTTCATTA 
> KRS fragment 
GTGTGACATGTTCTAATATAGTCACATTTTCATTATTTTTATTATAAGGCCTGCTGAAAATGACTGAATA
TAAACTTGTGGTAGTTGGAGCTGTTGGCGTAGGCAAGAGTGCCTTGACGATACAGCTAATTCAGAAT
CATTTTGTAGACGAATATGATCCCACAATAGAGGTAAATCTTGTTTTAATATGC 
> 3ʹ HA 
AATCATTTTGTAGACGAATATGATCCCACAATAGAGGTAAATCTTGTTTTAATATGCATATTACTGGTG
CAGGACCATTCTTTGATACAGATAAAGGTTTCTCTGACCATTTTCATGAGTACTTATTACAAGATAATT
ATGCTGAAAGTTAAGTTATCTGAAATGTACCTTGGGTTTCAAGTTATATGTAACCATTAATATGGGAA
CTTTACTTTCCTTGGGAGTATGTCAGGGTCCATGATGTTCACTCTCTGTGCATTTTGATTGGAAGTGT
ATTTCAGAGTTTCGTGAGAGGGTAGAAATTTGTATCCTATCTGGACCTAAAAGACAATCTTTTTATTG
TAACTTTTATTTTTATGGGTTTCTTGGTATTGTGACATCATATGTAAAGGTTAGATTTAATTGTACTAGT
GAAATATAATTGTTTGATGG 
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7.3 Reagents and recipes 
7.3.1. Freeze medium 
7.5 ml DMSO (Sigma Aldrich, USA) 
32.5 ml DMEM (Lonza, USA) 
10 ml FBS (Hyclone, USA) 
100 µl Pen/Strep (Lonza, USA) 
The DMSO, DMEM, FBS and Pen/Strep in a 50 ml tube. The mixture was filter sterilised 
with a 0.4 µm syringe filter and stored in the dark at 4ºC. 
7.3.2 Transformation buffer 
15 ml Glycerol (SaarChem, South Africa) 
1.47 g CaCl2.2H2O (Sigma Aldrich, USA) 
302.4 mg PIPES.HCl (Boehringer Manheim, Germany) 
NaOH (Sigma Aldrich, USA) 
ddH2O 
The glycerol, CaCl2.2H2O and PIPES.HCl were added together and made up to 80 ml with 
ddH2O. The solution was mixed with a magnetic stirrer. Once the CaCl2.2H2O and 
PIPES.HCl had dissolved and the solution was homogeneous, NaOH was added dropwise 
until the pH was exactly 7.0. The solution was made up to 100 ml with ddH2O, autoclaved 
and stored at -20ºC. 
7.3.3 Luria Bertani (LB) broth 
10 g Bacto-tryptone (Sigma Aldrich, USA) 
10 g NaCl (SaarChem, South Africa) 
5 g Yeast extract (Sigma Aldrich, USA) 
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ddH2O 
These were dissolved in 500 ml of ddH2O and then made up to 1 L. The broth was then 
autoclaved and stored at room temperature. 
7.3.4 Ampicillin 1 000X stock (100 mg/ml) 
5 g Ampicillin (Sigma, Aldrich, USA) 
25 ml of 100% Ethanol 
25 ml ddH2O 
The ampicillin was completely dissolved in a mixture of 25 ml of 100% ethanol and 25 ml 
ddH2O by vortexing. The ampicillin stock was stored at -20ºC. 
7.3.5 Ampicillin agar plates 
10 g Bacto-tryptone (Sigma Aldrich, USA) 
10 g NaCl (SaarChem, South Africa) 
5 g Yeast extract (Sigma Aldrich, USA) 
12.5 g Agar (Sigma Aldrich, USA) 
1 ml Ampicillin 1 000X stock (100mg/ml) 
ddH2O 
The bacto-tryptone, NaCl, yeast extract and agar were dissolved in 500 ml of ddH2O, made 
up to 1 L and autoclaved. The sterilised mixture was allowed to cool and 1 ml of ampicillin 1 
000X stock (100mg/ml) was added for a final concentration of 10 µl/ml. This was poured into 
bacterial culture petri dishes and allowed to solidify. The plates were then stored at 4ºC. 
7.3.6 Ampicillin-LB broth 
1 L LB broth 
1 ml Ampicillin 1 000X stock (100 mg/ml) 
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1 ml of ampicillin 1 000 X stock (100 mg/ml) was added to 1 L of cooled LB broth (for a 
final concentration of 10 µl/ml). This was stored at 4ºC. 
7.3.7 TAE buffer (50X) 
242 g Tris-base (Sigma Aldrich, USA) 
57.1 ml of 100% acetic acid (Merck, Germany) 
100 ml of 0.5 M sodium EDTA (pH 8.0) 
ddH2O 
The components were mixed together, dissolved in ddH2O and made up to 1 L. For a 1X TAE 
working stock, 20 ml of the 50X TAE solution was mixed with 980 ml of ddH2O. 
7.3.8 TBE buffer (5X) 
108 g Tris-base (Sigma Aldrich, USA) 
55 g of Boric acid (Merck, Germany) 
40 ml of 0.5 M sodium EDTA (pH 8.0)  
ddH2O 
The components were mixed together, dissolved in ddH2O and made up to 1 L. For a 1X TBE 
working stock, 100 ml of the 5X TBE solution was mixed with 900 ml of ddH2O. 
7.3.9 EDTA solution (0.5M, pH 8.0) 
93.06 g EDTA (Merck, Germany) 
ddH2O 
NaOH (Sigma Aldrich, USA) 
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The EDTA was dissolved in 400 ml of ddH2O using a magnetic stirrer. The pH of the solution 
was adjusted to 8.0 with NaOH. The solution was then made up to 500 ml with ddH2O.  
7.3.10 PBS (1X) 
PBS tablets (Sigma Aldrich, USA) 
ddH2O 
1 PBS tablet was dissolved in 250 ml ddH2O. The solution was autoclaved and store at 4ºC. 
7.3.11 Tris-HCl (1M, pH 8.0) 
60.55 g Tris-base (Sigma Aldrich, USA) 
HCl (Merck, Germany) 
ddH2O 
Dissolve Tris-base in 400 ml of ddH2O. Add HCl until the pH reaches 8.0. Make up the 
solution to 500 ml with ddH2O. 
7.3.12 TE buffer (10X) 
100 ml of 1M Tris-HCl (pH 8.0) 
20 ml of 0.5M EDTA (pH 8.0) 
ddH2O 
The Tris-HCl and EDTA solutions were mixed and made up to 1 L with ddH2O. The solution 
was filter sterilised with a 0.4 µm syringe filter and then autoclaved. 
7.3.13 Autoclaving conditions 
All autoclaving was performed at 121ºC at approximately 104 kPa for 20 minutes. 
!92
7.4 Protocols 
7.4.1 Competent E. coli Stbl3 cells 
8 ml of LB broth was inoculated with E. coli Stbl3 cells. These cultures were grown in a 
shaking incubator (180 rmp) for 16 hours at 37ºC. 2 ml of this culture was added to 48 ml of 
LB broth and placed back into the incubator until the cells reached the logarithmic growth 
phase. This was estimated using a spectrophotometer (OD600 = 0.4 - 0.6). The 50 ml culture 
was then removed and placed immediately on ice. The cells were then centrifuged at 4ºC at 
355×g (Boeco U-320R, Germany) for 10 minutes, after which the supernatant was poured 
off, and the pellet was very gently re-suspended in 1 ml of transformation buffer. Another 4 
ml of transformation buffer was added and the cells were placed on ice for 30 minutes. The 
cells were pelleted by centrifugation for 10 minutes at 160×g rpm (Boeco U-320R, Germany) 
at 4ºC. The supernatant was poured off and the pellet was gently resuspended in 1 ml of 
transformation buffer. 100µl aliquots of competent of cells were stored at -80°C. 
7.4.2 QIAprep Spin Miniprep Kit 
A 10 ml culture of transformed bacteria was cultured for 14-16 hours at 37ºC in a shaking 
incubator (180 rpm). The cells were harvested by centrifugation at 3 900×g (Boeco U-320R, 
Germany) for 10 minutes at 4ºC. The supernatant was discarded and the pellet was 
resuspended in 250 µl Buffer P1 and transferred to a microcentrifuge tube. 250 µl of Buffer 
P2 was added and the tubes were inverted 24 times and incubated at room temperature for 5 
minutes exactly. 350 µl of Buffer N3 was added and mixed by immediately inverting the tube 
24 times. The precipitant was collected by centrifuging the mixture for 10 minutes at 14 
000×g (Eppendorf 5402). The supernatant was then applied to a QIAprep spin column. The 
column was centrifuged for 30 seconds at 14 000×g (Eppendorf 5402) and the flow-through 
was discarded. The spin column was washed with 500 µl of Buffer PB by centrifugation at 14 
000×g (Eppendorf 5402) for 30 seconds and discarding the flow-through. The column was 
washed again with 750 µl of Buffer PE by centrifugation at 14 000×g (Eppendorf 5402) for 
30 seconds and discarding the flow-through. Residual wash buffer was removed by 
!93
centrifuging the tubes again for 1 minute. The QIAprep column was placed in a clean 
microcentrifuge tube and the DNA was eluted by adding 100 µl of Buffer EB to the centre of 
the column and incubating at room temperature for 1 minute. The DNA was collected by 
centrifugation at 16 000×g (Eppendorf Centrifuge 5402, Germany) for 1 minute.  
7.4.3 Qiagen Plasmid Midi Kit 
A 100 ml culture of transformed bacteria was culture for 14-16 hours at 37ºC in a shaking 
incubator (180 rpm). The cells were harvested by centrifuging 50 ml of the culture at a time, 
at 3 900×g (Boeco U-320R, Germany) for 15 minutes at 4ºC. The supernatant was discarded 
and the remaining 50 ml of the culture was added to the pellet and centrifuged again. The 
supernatant was then discarded and 4 ml of Buffer P1 was used to resuspend the pellet. 4 ml 
of Buffer P2 was added and mixed by vigorously inverting the mixture 24 times. The cells 
were incubated for 5 minutes at room temperature. 4 ml of pre-chilled Buffer P3 was then 
added and mixed by inverting the tube 24 times again. The mixture was then incubated on ice 
for 15 minutes before being centrifuged at 3 900×g (Boeco U-320R, Germany) for 30 
minutes at 4ºC. The supernatant was then carefully pipetted into a clean 15 ml tube and 
centrifuged again at 3 900×g (Boeco U-320R, Germany) for 15 minutes at 4ºC. In this time, 
an Qiagen-tip 100 was equilibrated by applying 4 ml of Buffer QBT and allowing for the 
column to empty by gravity flow. The supernatant from the centrifuged samples were added 
to the column and allowed to run through the resin by gravity flow. The Qiagen-tip 100 was 
then washed twice with 10 ml of Buffer QC each time. The DNA was eluted from the column 
by adding 5 ml of Buffer QF and allowing it to run into a clean 15 ml tube. The DNA was 
precipitated by adding 3.5 ml of room-temperature isopropanol and vortexing. The 
precipitated the DNA was collected by centrifugation at 3 900×g (Boeco U-320R, Germany) 
for 30 minutes at 4 ºC. The supernatant was carefully decanted and the remaining pellet was 
washed with 2 ml of 70% ethanol. The DNA was recollected by centrifugation at 3 900×g 
(Boeco U-320R, Germany) for 10 minutes at 4ºC. The supernatant was carefully decanted 
and the pellet was dried by placing the tube in a 50ºC heating block for 10 minutes. The pellet 
was then resuspended in 100 µl TE buffer. 
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7.4.4 QIAamp DNA Mini Kit 
Cells grown in a 6-well plate were harvested by washing the cells in each well with 2 ml of 
1X PBS and trypsinised with 1 ml Trypsin-EDTA (Hyclone, Thermo Scientific). The cells 
were incubated for 2-3 minutes at 37ºC, before 500 µl of complete DMEM was added to 
neutralise the trypsin. The cell suspension was then transferred to a 1.5 ml microcentrifuge 
tube and the cells were collected by centrifugation at 260×g for 5 minutes (Eppendorf 
Centrifuge 5402, Germany). The supernatant was then discarded, and the pellet was 
resuspended in 1 ml of 1X PBS and centrifuged again at 260×g for 5 minutes. This wash step 
was repeated. The final cell pellet was resuspended in 200 µl of 1X PBS. 20 µl of Proteinase 
K was added followed by 200 µl of Buffer AL. This was mixed by pulse vortexing the 
microcentrifuge tube for 15 seconds and incubated at 56ºC for 10 minutes. Droplets on the 
side of the tube were collected by brief centrifugation. 200 µl of 100% ethanol pre-chilled in 
a -80ºC freezer was added and mixed by pulse vortexing for 15 seconds. The microcentrifuge 
tube was briefly centrifuged again to collect droplets on the side of the tube. The mixture was 
then applied to a QIAamp Spin Column and centrifuged at 8 000×g for 1 minutes (Eppendorf 
Centrifuge 5402, Germany). The column was placed in a clean 2 ml collection tube and 500 
µl of Buffer AW1 was added and centrifuged at 8 000×g for 1 minute (Eppendorf Centrifuge 
5402, Germany). The column was placed in a clean 2 ml collection tube and 500 µl of Buffer 
AW2 was added and centrifuged at 16 000×g for 3 minutes (Eppendorf Centrifuge 5402, 
Germany). The column was then carefully placed in a clean 1.5 ml microcentrifuge tube and 
the DNA was eluted by adding 200 µl of Buffer AE and incubating at room temperature for 5 
minutes. The DNA was collected by centrifugation at 8 000×g for 1 minute. 
7.4.5 GeneJet Gel Extraction Kit 
The DNA band of interest was excised from the agarose gel using a clean scalpel and placed 
into a pre-weighed 1.5 ml microcentrifuge tube. The gel slice was then weighed and a 1:1 
volume of Binding Buffer was added to the gel slice (volume:weight). The gel slice was 
melted by incubating the mixture for 10 minutes at 50-60ºC and vortexing periodically. The 
mixture was then transferred to a GeneJet purification column and centrifuged for 1 minute at 
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8 000×g (Eppendorf Centrifuge 5402, Germany). The flow-through was discarded and 700 µl 
of Wash Buffer was added to the column and it was centrifuged for another minute at 8 
000×g (Eppendorf Centrifuge 5402, Germany). The flow-through was discarded and the 
residual buffer was removed by centrifugation at 8 000×g (Eppendorf Centrifuge 5402, 
Germany) for 1 minute again. The DNA was then eluted by transferring the GeneJet 
purification column into a clean 1.5 ml microcentrifuge tube and adding 50 µl of pre-warmed 
(65ºC) Elution Buffer to the centre of the purification column membrane. This was incubated 
for 1 minute at room temperature before being centrifuged for 1 minute at 16 000×g 
(Eppendorf Centrifuge 5402, Germany). 
  
7.4.6 GeneJet PCR Purification Kit 
This was carried out as described in section 7.4.5, however a 1:1 ratio of PCR and Binding 
Buffer volume was used instead. 
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7.5 Plasmid maps 
7.5.1 pcDNA.H1.sgRNA 
7.5.2 pCI-neo-eGFP 
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7.5.3 pJet 1.2 
7.5.4 pX330 
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7.6 Ethics approval waiver
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